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INTRODUCTION: Angiogenesis, the formation of new blood vessels from pre-
existing ones. It is a tightly regulated processes involving pro- and anti-
angiogenic molecules. Deregulation of this process is associated with aberrant 
blood vessel formation (excessive or insufficient) in several human 
pathologies. Among the many pro-angiogenic factors promoting 
angiogenesis, the vascular endothelial growth factor (VEGF) has been 
characterised as a major regulator of both physiological and pathological 
angiogenesis. Therefore, the characterisation of the molecular mechanisms 
that regulate VEGF-induced angiogenesis is essential to develop therapeutic 
strategies that correct abnormal angiogenesis. In this sense, our group has 
previously reported a negative role for the Plasma Membrane Calcium 
ATPase 4 (PMCA4) protein in endothelial cells, acting via inhibition of the pro-
angiogenic calcineurin/NFAT signalling pathway. However, we hypothesise 
that other intracellular pathways might be regulated by PMCA4 in endothelial 
cells during VEGF stimulation of angiogenesis.  
METHODS: To identify PMCA4 regulated pro-angiogenic signalling pathways, 
we have screened gene arrays related to Notch signalling or extracellular 
matrix-Cell Adhesion Molecule (ECM-CAM) pathway using RNA isolated from 
PMCA4-silenced (or control) HUVEC. Changes in gene expression after 
PMCA4 knockdown have been further validated by TaqMan-based qPCR in 
HUVEC or HDMEC. RNA levels of PMCA4 in aging HUVEC were analysed 
by TaqMan qPCR using RNA isolated from HUVEC cultured from different 
passages (from 3 to 15 passages). 
RESULTS: siRNA-mediated PMCA4 knockdown led to increased expression 




HUVEC. Expression of the transcription factor c-Fos was also elevated after 
PMCA4 knockdown in HUVEC stimulated with VEGF for 1h. Analysis of a 
gene array containing genes encoding extracellular matrix and cell adhesion 
molecules revealed that PMCA4 silencing alters the basal expression of P-
Selectin and L-Selectin in HUVEC. The expression of other genes in the array 
like, ADAMTS-1, E-Selectin, and VCAM-1, was affected by lack of PMCA4, 
but only when cells were stimulated with VEGF. Examination of changes in 
the expression of these genes in PMCA4-silenced HUVEC or HDMEC showed 
differences indicating that PMCA4 might differentially regulate these genes in 
different sub-types of endothelial cells. In conclusion, our results suggest that 
PMCA4 negatively regulates Notch signaling pathway, and it is required for 
proper synthesis of ECM-CAM molecules.  
A first step to investigate the expression of PMCA4 in endothelial cells during 
aging has shown that PMCA4 mRNA levels increase along cell culture 
passage in HUVEC. However, this initial result requires further verification of 
changes in PMCA4 protein levels and/or in other cellular types to conclude 



























During embryonic development, a simple vascular system originates by de 
novo synthesis from mesoderm-derived endothelial precursor cells 
(angioblasts) that give rise to a first network of blood vessels called primary 
capillary plexus. This process is known as vasculogenesis (Herbert and 
Stainier, 2011; Semenza, 2007). Remodelling of this primitive plexus into a 
complex functional circulatory system takes place by angiogenesis, that is 
defined as the formation of new blood vessels from pre-existing vasculature 
(Herbert and Stainier, 2011; Semenza, 2007).  In physiological conditions, 
angiogenesis is tightly controlled by a balance in the synthesis of pro-
angiogenic and anti-angiogenic growth factors (Iruela-Arispe and Dvorak, 
1997). However, imbalance between these factors leads to abnormal blood 
vessel formation, sometimes excessive, others insufficient, which has been 
associated with severe human pathologies (Carmeliet, 2003). 
1.1 PHYSIOLOGICAL ANGIOGENESIS 
 
1.1.1.a Angiogenesis in embryonic development 
Angiogenesis is the basic unit of physiological remodelling processes required 
for development, growth, and repair in the developing embryo (Coultas et al., 
2005). Human embryogenesis is a complex, multi-dimensional and 
heterogeneous process. Various mediators of angiogenesis such as vascular 
endothelial growth factor (VEGF) (Apte et al., 2019), acidic/basic fibroblast 
growth factor (aFGF/bFGF) (Fu et al., 1991) and platelet derived growth factor 
(PDGF) (Betsholtz, 2003) have been implicated in embryonic angiogenesis. 
Among them, VEGF and its receptors stand out as critical regulators of this 




(Carmeliet et al., 1996), even in heterozygous embryos (Hiratsuka et al., 
2005). Haploinsufficiency suggest that an appropriate dosage of VEGF is 
essential for proper vascular development, highlighting the importance of this 
factor.  As it will be described in detail later, VEGF is a homodimeric 
glycoprotein which induces endothelial cell (EC) proliferation, migration, 
differentiation, and permeabilization in the growing embryo in response to 
hypoxic micro-environment (Sciorio and Smith, 2019). Hypoxia is a strong 
driving factor of angiogenesis (Sciorio and Smith, 2019). Oxygen metabolism 
plays an important role in the developing embryo. Oxygen levels in the 
developing embryo are extremely low (<3%-Hypoxia), which is critical in 
stimulating the angioblasts to divide and form the primary vascular plexus that 
later will be remodelled to form functional blood vessels in the embryo (Sciorio 
and Smith, 2019; Sherer and Abulafia, 2001). The endothelial basement 
membrane is degraded in response to VEGF, and new blood vessels are 
formed towards the region of hypoxia by sprouting or intussusceptive 
angiogenesis. Sprouting angiogenesis is initiated by basement membrane 
degradation, mural cell detachment, EC tip/stalk cell determination, EC 
proliferation, migration and finally establishment of vessel homeostasis (Duran 
et al., 2017) (Figure 1.1.i). It is controlled by activation of conserved signalling 
pathways. Among them, NOTCH signalling pathway is particularly important 
in regulating the tip/stalk cell response mediated by VEGF gradient (Ferrara 
et al., 2003). During the absence of VEGF gradient, intussusceptive 
angiogenesis occurs by circumferential enlargement of vessels followed by 





Figure 1.1.i Diagrammatic representation of the two types of 
angiogenesis. In sprouting angiogenesis, the new blood vessels are formed 
from pre-existing vasculature with the help of tip cells and trailing stalk cells 
which fuses together to form nascent blood vessel. In intussusceptive 
angiogenesis, lumen is split into two to form new blood vessels. 
 
1.1.1.b Angiogenesis in wound healing 
In response to tissue injury, the ECs migrate forming capillary vessels and 
granulation tissue to supply oxygen and nutrition to the affected area (Li et al., 
2003). Wound healing is a three-phase process which involves inflammation, 
proliferation, and extra cellular matrix remodelling. A number of cells 
participate in wound healing like fibroblasts, smooth muscle cells, endothelial 
cells, immune cells, etc (Li et al., 2003; Shah et al., 2012). Most potent 
regulators of tissue remodelling in this dynamic process are VEGF (Bao et al., 
2009), fibroblast growth factors, and angiopoietins (Li et al., 2003; Tonnesen 
et al., 2000) which are secreted by wide range of cell types and tissues. While 




deposition (Bao et al., 2009; Takahashi and Shibuya, 2005).  Ang-1 promotes 
tight non-leaky vasculature in vivo (Li et al., 2003). FGF promotes fibrin 
deposition at the site of tissue ablation leading to clot formation which aids in 
the migration of ECs through the clot (Grazul-Bilska et al., 2003). There are 
numerous signalling cascade mechanisms and interactions occurring 
between the ECs and the extra cellular matrix (ECM) components which 
provides a provisional scaffold required during the process of healing (Li et al., 
2003). At the first instance the wound develops a matrix immediately within 
few hours after injury which is followed by inflammation induced by cytokines. 
The inflammatory phase involves neutrophil and monocyte recruitment. 
During the proliferative phase, capillary sprouting and neovascularization 
occurs where the extra cellular matrix components stabilize the newly formed 
blood vessels (Shah et al., 2012). 
1.1.1.c Angiogenesis in the female reproductive system 
Angiogenesis is important in female reproductive system during 
decidualization which is accompanied by vascularization of stromal bed during 
early pregnancy (Okada et al., 2018; Redmer and Reynolds, 1996). Female 
reproductive organs serve as an excellent model to study the periodic growth, 
differentiation, and regression of blood vessels (Reynolds et al., 1992). Pro-
angiogenic and anti-angiogenic regulators are produced by uterine, placenta, 
corpus luteum, and ovarian tissues which helps in extra-cellular matrix 
remodelling (Reynolds et al., 1992). Endometrial vascularization is aided by 
several key angiogenic regulators like VEGF (Reynolds et al., 1992), relaxin 
(Parry and Vodstrcil, 2007), fibroblast growth factor (FGF) (Estienne and 




several pathologies in the female reproductive system like endometriosis 
(Danastas et al., 2018), ovarian carcinoma, failed implantation, etc (Reynolds 
et al., 2002). Angiogenesis is required for regeneration of the endometrial 
layer after shredding in menstrual cycle. The menstrual life cycle consists of 
three phases: the menstrual phase, proliferative phase, and the secretory 
phase (Punyadeera et al., 2006).  VEGF is highly expressed in the menstrual 
and early proliferative phase, but levels decline in the late proliferative phase 
(Punyadeera et al., 2006). Changes in VEGF expression during the different 
phases of the menstrual cycle underlie the relevance of angiogenesis in this 
process (Punyadeera et al., 2006).  
1.2 PATHOLOGICAL ANGIOGENESIS  
Abnormal formation of blood vessels due to excessive or insufficient 
angiogenesis is associated to several human pathologies (Ribatti D., 2005). 
Furthermore, VEGF is known to mediate vascular permeability leading to a 
leaky vascular environment and infiltration of inflammatory cells that is also 
present in many vascular pathologies (Ribatti D., 2005). 
1.2.1. PATHOLOGY ASSOCIATED WITH EXCESSIVE ANGIOGENESIS  
1.2.1.a Tumor angiogenesis 
Tumor cell populations are heterogeneous in nature consisting of stromal 
cells, extracellular matrix components and infiltrated vasculature (Pradeep et 
al., 2005). These cells require access to the vasculature for oxygen and 
nutrients due to active proliferation. They acquire oxygen either by preying on 
the nearby non-malignant cells (termed as ‘co-option’) (Kuczynski et al., 2019) 




of new blood vessels from pre-existing ones (Lugano et al., 2020). VEGF-A is 
highly expressed in almost all tumor types, induced by a number of factors like 
low pH, hypoxia, inflammatory cytokines, hormones or due to inactivation of 
tumor suppressor genes (Kerbel, 2008). It has been described that VEGF 
receptors 1 and 2 play a major regulatory role in EC barrier function. Blockade 
of these receptors leads to less tumor extravasation in vivo (Lee et al., 2010). 
Thus, targeting VEGF and/or its receptor has a valuable potential as an anti-
tumor therapeutic tool. However, anti-VEGF/VEGF-R approaches have only 
shown limited benefits in patients so far. Trials using Bevacizumab, an anti-
VEGF human monoclonal antibody that blocks binding of VEGF to its receptor, 
only showed improved survival of 4-5 months in patients with advanced 
colorectal cancer. After an initial brief period of regression, a high percentage 
of patients develop resistance to the anti-VEGF therapy which may be 
associated with the expression of other pro-angiogenic factors such as bFGF 
(Bergers and Hanahan, 2008; Mitsuhashi et al., 2015).  Moreover, another 
problem of anti-VEGF therapy is that the drugs not only act on tumor cells but 
also disrupt the physiological availability of VEGF required for normal 
functions. Blockage of the physiological effects of VEGF on the cardiovascular 
system resulted in severe side effects in patients. Established evidence has 
proven that VEGF is arterio-protective and maintains vascular integrity as it 
stimulates synthesis of endothelial NO and PGI2 (Laitinen et al., 1997). Tumor 
patients receiving Bevacizumab in combination with standard chemotherapy 
show increased blood pressure and cardiotoxicity when compared with those 
receiving standard care alone (Laitinen et al., 1997). Anti-VEGF drugs also 




to low production of NO and PGI2 levels endogenously (Laitinen et al., 1997; 
Wheeler-Jones et al., 1997). Therefore, a full understanding of the molecular 
mechanisms implicated in the response of endothelial cells during tumoral 
angiogenesis is required to design proper anti-angiogenic therapies to treat 
tumor progression. 
1.2.1.b Diabetic retinopathy 
Diabetic retinopathy is a leading cause of ocular disease leading to 
progressive vision loss in patients over 65 years. Investigations into the 
biological processes underlying the pathogenesis of this complication have 
shown that chronic exposure of diabetic eye to hyperglycaemia triggers a 
number of biochemical events that resulted in retinal endothelial dysfunction 
(Fong et al., 2004). Progression to the most severe, vision-threatening forms 
of retinopathy is characterised by an increase in vascular permeability and 
retinal neovascularisation, leading to diabetic macular edema (DME) and 
proliferative diabetic retinopathy (PDR), respectively (Fong et al., 2004). 
Evidence from several groups demonstrated that levels of VEGF are elevated 
in the vitreous and aqueous fluids of diabetic patients diagnosed with PDR or 
DME (Aiello et al., 1994; Adamis et al., 1994). It is now well established that 
VEGF plays a critical role in the formation of new, highly permeable blood 
vessels that represent the hallmark of diabetic retinopathy (Cheung et al., 
2010). As described more in detail later in section 1.5.1, alternative splicing of 
the VEGF gene generates several VEGF isoforms. VEGF121 and VEGF165 
are the major isoforms expressed in healthy eyes (Kim et al., 1999). Both 
VEGF121 and VEGF165 induce vascular permeability and endothelial cell 




shown that VEGF165 is approximately twice as abundant as VEGF121 during 
physiological retinal vascularisation, however ischemia-induced pathological 
retinal neovascularisation is associated to a 25-fold increase in the expression 
of VEGF165 (with respect to VEGF121 expression), suggesting that VEGF165 
is the main isoform implicated in the progression of pathological ocular 
neovascularisation (Ishida et al., 2003). Anti-VEGF therapies using 
monoclonal antibodies Bevacizumab (Minnella et al., 2008) and Ranibizumab, 
or the aptamer Pegaptanib (Klettner and Roider, 2008) (an anti-VEGF agent 
that specifically inhibits the isoform VEGF165) showed benefits to treat 
aggressive disease but disease progression was observed after two years 
(Klettner and Roider, 2008). Although anti-angiogenic therapies show 
enormous potential, there is a clear need to improve current treatments for the 
treatment of diabetic retinopathies. 
1.2.2. PATHOLOGY ASSOCIATED WITH INSUFFICIENT ANGIOGENESIS 
 1.2.2.a Ischemic heart disease 
Ischemic heart disease (IHD) is caused by insufficient or no supply of oxygen 
to the heart due to narrowing of cardiac blood vessels due to clots or plaque 
deposition (atherosclerosis) which may cause the death of cardiomyocytes, 
fibroblast and endothelial cells, and lead to cardiac hypertrophy and heart 
failure. Although several pharmacological interventions like coronary bypass, 
grafting, or angioplasty exist, the chances of recurrent heart failure are higher 
in patients with ischemic heart disease. These patients may be benefited from 
therapeutic strategies involving angiogenic activator molecules delivered by 




2002). VEGF is reported to have anti-thrombolytic properties. It prevents 
endogenous and exogeneous coagulation within a blood vessel. It increases 
the level of nitric oxide (NO) and prostacyclin (PGI2) within the blood vessel 
(Laitinen et al., 1997; Wheeler-Jones et al., 1997). NO is a potent inhibitor of 
platelet aggregation (Suchyta et al., 2014). VEGF also promotes the 
expression of serine proteases, which helps in production of plasmin leading 
to thrombolysis (Hui-Liang Zhang et al., 2017; Ambra et al., 2019). 
VEGFA/VEGF-R plays an important role in the cardiac response during early 
events of myocardial infarction (MI) (Zhao et al., 2010; Ucuzian et al., 2010). 
Studies in rat myocardium showed VEGF mRNA and protein levels increase 
in the infarct border zone at day 1 post-MI and decrease thereafter. In the 
infarcted region of the heart VEGF levels gradually reduces after day 1 up to 
4 weeks. VEGF-R density in the border zone increase during day 1 and 
returned to normalcy at day 3 whereas in the infarcted heart, it decreased 
during day 1 and returned to normal afterwards. VEGF-A and VEGF-R levels 
are reduced in newly generated micro vessels in the infarcted heart post MI. 
However, VEGFR levels returned to normalcy after day 1 whereas VEGF 
levels remain low suggesting that VEGF levels are critical in stimulation of 
angiogenesis during early stage and not implicated at later stages of the 
cardiac response to MI (Zhao et al., 2010). These studies have highlighted the 
involvement of VEGF and its receptor in the post-MI cardiac response. Thus, 
therapeutic approaches to deliver VEGF to the ischaemic heart have attracted 
huge attention as potential strategies to increase cardiac reperfusion after MI 
events.  Protein therapy to deliver pro-angiogenic cytokines like FGF-2 or 




(Chu and Wang, 2012). Pre-clinical trials in stress induced ischemic animal 
models using gene therapy (plasmids or adenovirus) showed significant 
improvement in perfusion and heart function (Chu and Wang, 2012). Although, 
these methods show vascular perfusion, their efficacy remains low.  
 1.2.2.b Peripheral arterial disease 
Peripheral Arterial Disease (PAD) is an atherosclerotic disease mainly caused 
by plaque deposition lining the vascular bed. It is characterised by occlusive 
blood flow to the lower extremities due to narrowing of arteries (Olson and 
Treat-Jacobson, 2004). People with diabetes, hypertension, hyperlipidaemia 
are at increased risk of this disease (Khattab et al., 2005). The risk of PAD 
increases with age, affecting both men and woman older than 60 years 
(Falconer et al., 2008). It can be either symptomatic or asymptomatic both 
requiring treatment against cardiovascular complications and relief of 
symptoms like intermittent claudication leading to Critical limb ischemia (CLI) 
and amputation (Olson and Treat-Jacobson, 2004; Collins et al., 2005). 
Symptomatic PAD is characterised by intermittent claudication ‘limping’ 
causing severe cramping of leg muscles due to insufficient flow of blood 
supply to meet with metabolic demand (Collins et al., 2005). Over 20-30% of 
people with PAD have diabetes mellitus and are at 10 to 20-fold risk to develop 
CLI (Thiruvoipati et al., 2015; Hochberg et al., 2001). VEGF has been 
identified as a critical inducer of collateral blood vessels in the occluded area 
of peripheral arteries. VEGF-165 delivery in animals induced by gene therapy 
or protein therapy showed increase reperfusion in models of experimentally 
induced hindlimb ischemia (Chu and Wang, 2012). However, over-expression 




vasculature and tissue inflammation (Hochberg et al., 2001; Chu and Wang, 
2012).  Phase I/II clinical trials of gene therapy via delivery of adenovirus 
carrying vegf or fgf showed promising safety but not satisfactory efficacy (Chu 
and Wang, 2012).  Intra-muscular gene therapy of VEGF-165 is given to 
patients with severe chronic lower limb ischemia who failed to meet with 
conventional therapy. Promising therapeutic effects were observed in patients 
with long term dose dependent treatment of plasmids carrying VEGF-165 
gene although clinical benefit was not achieved (Anghel et al., 2007). All these 
studies indicate that despite extensive research in this area, the promising 
results obtained in preclinical settings have not been translated into clinical 
benefits for patients. Hochberg et al., 2001 have shown that diabetic patients 
with CLI present higher levels of VEGF than diabetic patients without CLI, 
suggesting that production of VEGF is not a limiting factor in diabetic patients 
with CLI and might be the reason why VEGF-based therapeutic approaches 
have not yielded any clinical benefits. Therapeutic approaches that deliver 
alternative pro-angiogenic factors are currently being investigated in this area.   
1.2.2.c CLINICAL DEVELOPMENT IN PRO/ANTI-ANGIOGENIC 
THERAPIES 
As we look at further sections of this thesis, VEGF is an important pro-
angiogenic factor studied widely with regards to its angiogenic stimulating 
property. A number of clinical studies involving anti-VEGF molecules to target 
life threatening diseases exist but in all cases the patients suffer 
disadvantages. For example, tumor progression after a stable progression 
free survival may be due to the involvement of other proangiogenic factors or 
alternative survival pathways. Therefore, combination therapies with 




than two genes to target pathologies are gaining attention (Spooner et al., 
2019, Barc et al., 2020). A clinical study involving the evaluation of safety and 
efficacy profile of anti-VEGF drugs Aflibercept, Bevacizumab, Ranimazizumab 
shows comparable effects in patients with Cystoid macular Edema (CME) 
secondary to Branch Retinal Vein Occlusion (BRVO) (Spooner et al., 2019). 
Treat and Extend (T&E) randomized trials are increasingly popular in 
opthalmological pathologies like neovascular age related macular 
degeneration (AMD) or patients with diabetic macular edema (DME) (Amoaku 
et al., 2018). LUCAS (Lucentis Compared to Avastin Study) is a Norwegian 
multicentre, randomized clinical trial with (n=371) subjects divided into two 
groups. The subjects were randomized to receive either Ranimazizumab 
0.5mg (n=187) or Avastin 1.25mg (n=184) on a monthly basis. The two years 
study revealed that the two drugs had equivalent effect on safety and efficacy 
between the two groups (Berg et al., 2016, Khanna et al., 2019). TREND 
(TReat and ExtEND) study, which is a US based multicentre, randomized trial 
involving n=650 subjects was studied in patients with wet age-related macular 
degeneration. N=327 received 0.5mg Ranimazizumab (monthly) or n=323 
subjects received 0.5mg Ranimazizumab based on T&E protocol. The 
outcome of the study showed that subjects from T&E cohort were clinically 
benefitting (Berg et al., 2016). 
While the above-mentioned studies aimed to inhibit angiogenesis, there has 
also been major advancements in involving VEGF as a therapeutic target to 
improve angiogenesis to treat life threatening pathologies like the Ischemic 
diseases or Peripheral Arterial Diseases (PAD). Although there are many 




therapy available to treat conditions related to inadequate blood supply, the 
use of growth factors like VEGF, HGF has gained attention due to its ease of 
delivery and targeting.  
Protein therapy trial using recombinant VEGFA-165 has shown clinical 
benefits in patients with cardiovascular disease. Phase I clinical trial in patients 
with angina showed safety and tolerability and improved myocardial perfusion 
(Henry et al., 2001). Pharmacokinetic analysis showed improved uptake of 
rhVEGF by binding to endothelial receptors and heparin proteoglycans. Phase 
II VIVA trial (VEGF in ischemia for vascular angiogenesis) was done in n=178 
patients randomized to receive Intracoronary infusion of placebo or low dose 
rhVEGF or high dose rhVEGF followed by 4 hours intravenous infusion and 
assessed at 60 and 120 days. Results showed no significant improvement in 
anginal score after 60 days in placebo or low dose treated groups. However, 
after 120 days, at high dose of rhVEGF, there was significant improvement in 
anginal score with good safety and tolerability to the therapy. Although this 
treatment regimen is good, it suffers limitation of short half-life of VEGF (Henry 
et al., 2003). 
Gene therapy for sustained delivery of cytokines using plasmid vectors or 
adenovectors has shown excellent therapeutic efficiency. In a phase I clinical 
trial using cDNA plasmids encoding VEGFA-165, phVEGF165 by 
Intramyocardial injection via thoracotomy guided by catheter provided 
feasibility in a double blinded pilot study. Following this, several clinical trials 
followed this treatment route like the EUROINJECT-ONE and NORTHERN 
clinical trials (Kastrup et al., 2005; Stewart et al., 2009). Both trials showed no 




TALISMAN, TAMARIS trials using plasmid vectors with FGF-1 showed 
negative results (Nikol et al., 2008). Mostly trials using plasmid vectors 
showed to be negative due to low transfection efficiency of the plasmids 
(Zachary & Morgan, 2011). 
The adenoviral vectors are so far preferred for treating coronary vascular 
disease. In a phase I clinical trial involving n=21 subjects with Coronary Artery 
Disease treated with intramyocardial AdVEGF-121 via thoracotomy showed 
to be safe and well tolerated. REVASC trial using AdVEGF-121 
intramyocardial injection via mini thoracotomy showed significant 
improvement in anginal symptoms in treatment group compared to control 
group (Stewart et al., 2006). In another clinical study, patients with Critical limb 
Ischemia complicated by Diabetes mellitus were given an intramuscular 
injection of pIRES/VEGF-165/HGF which is a double VEGF/HGF gene 
therapy delivering the bicistronic plasmid vector. One group received the 
intramuscular injection while the second group was a control group and did 
not receive the plasmid. Based on the observation, the treatment regimen was 
safe and effective but is only reliable when applied at the early stage of 
disease progression (Barc et al., 2020). 
1.3 CELLULAR EVENTS IN ANGIOGENESIS 
ECs tightly regulate the integrity of the blood vessel wall. ECs in sprouting 
blood vessels have a   heterogenous   structure (continuous, fenestrated, or 
discontinuous) (Aird, 2007), phenotype (arterial, venular, capillary or 
lymphatic) (Phng and Gerhardt, 2009) and function (permeability, proliferation, 




Gerhardt, 2009). Sprouting angiogenesis is a complex multi-stage process 
that can be basically divided into 4 steps (Figure 1.3.i). The first stage is a 
quiescent stage where the monolayer of ECs bears tight junctions with an 
intact basement membrane, essential for barrier functions, and with pericytes 
and smooth muscle cells (Figure 1.3.i). Sprouting angiogenesis begins with 
activation of ECs along the pro-angiogenic gradient in response to hypoxia/ 
injury leading to vascular dilatation which allows invasion of proteins that 
disrupt the endothelial basement membrane (Carmeliet and Jain, 2011). 
During this stage, extra cellular matrix is degraded, by proteases like those of 
the matrix metalloprotein family (MMPs) or suppressors of protease inhibitors 
like tissue inhibitor of metalloprotienase-2 (TIMP-2) (Jain, 2003) and 
endothelial cells lose their cell-cell junctions. Mural cells (vascular smooth 
muscle cells (VSMC), pericytes and fibroblasts) detach from the vessel wall. 
At stage 2, some ECs differentiate into “Tip cells” (TC) located at the growing 
end of the sprout (Figure 1.3.i). TC selection is regulated by the VEGF gradient 
(Jain, 2003). Tip cells guide the angiogenic sprout in the direction of the 
angiogenic stimulus. Every angiogenic sprout contains a single tip cell (Phng 
and Gerhardt, 2009; Jakobsson et al., 2009). The TC is followed by “Stalk 
cells” (SC) which provides support to the growing sprout and forms lumen. Tip 
versus stalk cell selection is tightly co-ordinated by the Delta like ligand 4 
(DLL4/NOTCH signalling axis (Hellstrom et al., 2007). Stalk cells stop 
proliferating when the tip cell of a growing sprout anastomose with a tip cell 
originated from another sprout, which then fuse to form a nascent blood vessel 
(stage 3, Figure 1.3.i). The mechanism of anastomosis is thought to be 




growing sprout by regulation of membrane localized Flt1 (mFlt1) receptor 
(Nesmith et al., 2017). The newly formed blood vessel undergoes a series of 
molecular interactions between and within the layers of vascular beds (EC-
EC; EC-Mural cells; EC-ECM) to form a stable network (stage 4, Figure 1.3.i) 
(Jain, 2003). Basement membrane reinforces, and the monolayer of 
endothelial cells is established and develops tight junctions. The process of 
angiogenesis continues until the angiogenic stimulus cease and the mature 
new blood vessels attain a quiescent state (Jain, 2003). 
 
Figure 1.3.i. Diagrammatic representation of various stages involved in 
formation of sprouting angiogenesis in response to angiogenic stimuli. 
1) Quiescent Vessels: Monolayer of inactive EC with tight junctions, mural 
cells and basement membrane remain intact on the vessel wall; 2) Tip Cell 
selection: Angiogenic stimulus causes the EC to lose their cell-cell tight 
junctions, ECM and basement membrane degradation, pericytes and SMC 
detachment. Some ECs are selected as “Tip Cells”; 3) Stalk Elongation and 
Anastomosis: Tip cells are trailed by stalk cells that proliferate and establishes 
lumen, tip cells from two sprouting vessels anastomose; 4) Vessel Maturation: 
nascent blood vessels are stabilized by recruitment of pericytes and SMC. 
ECM, basement membrane and EC cell tight junctions are re-established. 




1.4 REGULATORS OF ANGIOGENESIS 
As we have seen in the previous section the process of angiogenesis is initiated 
in response to proangiogenic stimuli. Research in the last decades have 
identified several pro- and also anti-angiogenic factors that modulate the 
angiogenic process by binding to specific receptors in the membrane of ECs 
leading to activation of specific intracellular signalling pathways (Table 1.4.a 
and table 1.4.b) (Milkiewicz et al., 2006). 
Table 1.4.a. STIMULATORS OF ANGIOGENESIS. The table below shows 
selected molecules involved in the process of stimulating angiogenesis 





growth factor (VEGF) 
 
VEGFA-VEGFR1/VEGFR2:EC 
proliferation migration, ECM 
degradation, tube formation, 
increase in vessel permeability 








 Activation of TF Ets-1 release 
HGFs to maintain a positive 
feedback loop on EC. 
 Regulates cell motility. 
 Negatively regulates TSP-1 
(Suppressor of Angiogenesis) 
(Milkiewicz et al., 2006). 
 EC and SMC proliferation and 









 EGF-EGFR (HER1) or HER2-4: 
Induces VEGF production via 
HIF 1α protein synthesis 
(Milkiewicz et al., 2006). 
 Increase epithelialization and 
shortened healing time for skin 
graft, diabetic foot ulcers 
(Bodnar, 2013). 
 Overexpressed in solid tumors 







 FGF2/FGFR1 – Migration and 
differentiation of EC 
 FGF2/FGFR2 – Only migration 
(Milkiewicz et al., 2006) 
 EC proliferation, migration, ECM 





 PG/COX2 – EC survival & 
migration (Milkiewicz et al., 
2006) 
 
 Synergism between PG/FGF2 
signalling pathways, promotes 






 HIF1α/HIF1β dimerization acting 
as an inducer of HRE (hypoxic 
Response Elements) 
 Increases transcription of >60 
genes important in hypoxic 
adaption via PI3K signalling 





Table 1.4.b. INHIBITORS OF ANGIOGENESIS. The table below shows 
selected regulatory molecules involved in the process of inhibiting 
angiogenesis controlled by various molecular mechanisms. 
 
MOLECULES FUNCTION 
Angiostatin  Inhibits EC proliferation & 
neovascularisation; increases 
apoptosis. 
 Antagonistically binds to cmet, 
blocking HGF/cmet signalling 
pathway (Milkiewicz et al., 
2006) 
 Angiostatin/IL-12- Anti 
angiogenic activity as an 
immune modulator (Albini et al., 
2009) 
Endostatin  Inhibits VEGF induced 
migration binding to VEGFR2 
directly. 
 Promotes EC apoptosis. 
 Inhibits catalytic activity of 
MMP2 & MT1-MMP decreased 
EC invasion (Milkiewicz et al., 
2006) 
 Endostatin/TSP-1- Leads to 
increase in TSP-1 expression, 
anti angiogenic (Faye et al., 
2009) 
 Endostatin/VEGFR-3- Inhibits 
lymphangiogenesis (Han et al., 
2021) 
Thrombospondin TSP1 & TSP2 
 Inhibitors of angiogenic 
sprouting by antagonistic 
activity of VEGF. 
 Activates Apoptosis (Milkiewicz 




 TSP4/Integrin α2/HSF-1 
promote EC proliferation in Gall 
bladder cancer via Akt pathway 
(Shi et al., 2021) 
 
TIMP (Tissue Inhibitor 
of Angiogenesis) 
TIMP-2  
 Inhibits EC proliferation (PTP, 
Shp-1 signalling pathways). 
Inhibits MMPs & selecting 
interact with MT1-MMP (Stetler-
Stevenson and Seo, 2005). 
Induce cell cycle arrest at G1 
phase- Anti apoptotic activity 
(Brew & Nagase 2010). 
 
As it has been mentioned before in sections 1.1 and 1.2, vascular endothelial 
growth factor (VEGF) stands out as a key pro-angiogenic factor implicated in 
the formation of new blood vessels in both, physiological and pathological 
conditions. VEGF has been used extensively in this research project to 
activate pro-angiogenic gene expression in endothelial cells and thus, a more 
detailed description of the VEGF features is included in this introduction. 
1.5 VASCULAR ENDOTHELIAL GROWTH FACTOR FAMILY 
The vascular endothelial growth factors belong to a protein family that 
comprises seven members: VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, 
svVEGF (snake venom VEGF) and PLGF (placental growth factor) (Takahashi 
and Shibuya, 2005). Among the several members of the VEGF family, VEGF-
A has been identified as the major pro-angiogenic factor and is of particular 
interest for the study conducted in this thesis. For that reason, I focus on the 





VEGF-A is a dimeric glycoprotein that is produced by several cells and tissues. 
In humans, the VEGF-A gene spans around 14Kb with 8 exons and 7 introns. 
Alternate splicing of the VEGF-A gene into different specific combinations of 
functionally active exons generates distinct VEGF-A isoforms with different 
length (VEGF-A183, VEGF-A121, VEGF-A145, VEGF-A148, VEGF-A165, VEGF-
A189 and VEGF-A206) (Peach et al., 2018). Some of the protein’s variants 
synthesized by translation of these transcripts are produced as soluble 
proteins, whereas others can bind to the ECM that can act as a VEGF 
reservoir. Exons 1-5 (Figure 1.5.i) are included in all isoforms of VEGF-A. 
VEGF-A121 lack exon 6 and 7 which encode the fragment of the VEGF protein 
responsible for binding to the ECM. Thus, this variant does not bind to ECM 
and is soluble (Grünewald et al., 2010). VEGF-A145, VEGF-A183, VEGF-A189 
and VEGF-A206 retain part or the whole of exon 6 and 7 (Figure 1.5.i). These 
isoforms bind to ECM with high affinity and are not freely diffusible. VEGF-A165 
and VEGF-A145 are an intermediate between ECM-bound and freely soluble 
isoforms (Grünewald et al., 2010; (Woolard et al., 2009). Further, splicing of 
exon 8 can generate isoforms lacking exon 8a but containing exon 8b. These 
isoforms are called VEGF-Axxxb (where xxx represents amino acid length) and 
only differ from VEGF-Axxx in the last 6 amino acids of the C-terminus. VEGF-
Axxx isoforms are associated with the physiological functions described for 
VEGF (pro-angiogenic properties, induction of vascular permeability and cell 
survival). However, VEGF-Axxxb isoforms have been reported to have anti-
angiogenic properties (Peach et al., 2018). An additional isoform of VEGF-A 




translation further to the canonical stop codon of VEGF-A isoforms located in 
exon 8a (Eswarappa et al., 2014). Compared to VEGF-A165, RNA translation 
in VEGF-Ax extends further to exon 8a incorporating a new sequence of 16 
amino acids and the 6 amino acids corresponding to exon 8b (Figure 1.5.i). 
The physiological role of VEGF-Ax has not been fully elucidated yet. Initially it 
was described as a VEGF-A variant with anti-angiogenic properties 
(Eswarappa et al., 2014). However, a later work by Napoleone Ferrara’s group 
has reported that VEGF-Ax exerts mitogenic, angiogenic and permeability 
enhancing functions in endothelial cells (Xin et al., 2016). The reason for this 
discrepancy is not clear at present.  
 
 
Figure 1.5.i Exon assembly of vascular endothelial growth factor A 
(VEGF-A). Exon variations in VEGF-A isoforms generated by alternative 
splicing along the mRNA are shown. After post-translational modification, the 
newly formed proteins are ready to bind to their specific receptors. (adapted 




1.6 VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTORS (VEGFR) 
VEGF-A isoforms bind to specific tyrosine kinase receptors (VEGFRs), which 
consist of an extracellular ligand binding domain, a transmembrane domain 
and an intracellular domain possessing inducible tyrosine kinase regions. 
Three different VEGFRs have been identified, VEGFR-1, VEGFR-2 and 
VEGFR-3, with variable ligand affinities and tyrosine kinase activity. VEGF-A 
binds to VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk in mice) activating different 
downstream cellular responses in each case (Sakurai et al., 2005). VEGF-
C/VEGF-D bind to VEGFR-3 and mediate lymphangiogenesis (Figure 1.6.i). 
 
Figure 1.6.i Diagrammatic representation of different isoforms of VEGF 
receptors and their ligands. The binding of ligands on to specific receptors 
leads to several cellular and physiological effects mediated by various 
downstream signaling pathways important in angiogenesis. (adapted from 







VEGFR-1 is a 180-185 kDa glycoprotein which has affinity to bind to VEGF-A 
or VEGF-B in its extracellular domain. Global knockout of VEGFR-1 in null flt-
/- mice causes embryonic lethality, with embryos showing overgrowth of EC 
and disorganized blood vessel formation in E8.5 (Sakurai et al., 2005; Koch 
and Claesson-Welsh, 2012). These results suggest that VEGFR-1 plays a 
negative regulatory role in angiogenesis. In agreement with this idea, VEGFR-
1 has been characterized as a decoy receptor and is not driven by VEGF 
gradient to promote angiogenesis. VEGFR-1 has high affinity to bind VEGF-A 
compared to VEGFR-2, but kinase activity is lower than its latter (Peach et al., 
2018). The VEGFR-1 (Flt-1) gene expresses 2 mRNAs: long (8 kb), and short 
form (2.5 to 3.0 kb). Short forms are expressed in the placenta and known as 
soluble Flt-1 (sFlt-1). They are very important to maintain barrier function of 
the placenta and to avoid abnormal vascular permeability (Shibuya, 2011). 
1.6.2 VEGFR-2 
VEGFR-2 is a 151 kDa a membrane bound glycoprotein consisting of 7 
extracellular immunoglobulin-like domains, a transmembrane domain, and an 
intracellular tyrosine kinase domain. VEGFR-2 is the key VEGF receptor of 
endothelial cells (Koch and Claesson-Welsh, 2012). All VEGF-A isoforms can 
bind VEGFR-2 (Peach et al., 2018).  But the activation of receptors varies in 
each case. Binding of VEGF-A/VEGFR-2 initiates a conformational twist or 
rotation of the transmembrane helix domain. Then the intracellular domain 
undergoes a conformational change of N and C lobes (Peach et al., 2018).  
ATP binds to the N lobe and transactivates tyrosine phosphorylation of the C 




signaling pathways. Phosphorylation of Y951 mediates regulation of cell 
adhesion, vascular permeability, and cell survival via the PI3K-AKT pathway 
(Peach et al., 2018; Koch and Claesson-Welsh, 2012).  P-Y1175 recruits 
PLCγ and triggers Ca2+ dependent signaling leading to EC proliferation and 
migration (Koch and Claesson-Welsh, 2012). VEGFR-2 can be quickly 
recycled to cell surface after being internalized to maintain persistent 
intracellular signaling, thereby regulating endosomal as well as plasma 
membrane signaling. VEGF/VEGFR signaling is a highly conserved 
mechanism which is linked with other pathways like Angiopoietin/Tie2 or 
DLL4/NOTCH signaling to mediate tight regulation of angiogenesis (Shibuya, 
2011). 
1.6.3 VEGFR-3 
VEGFR-3 (Flt-4) is expressed on all endothelial cells during embryonic 
development and becomes restricted to lymphatic endothelium in the adult 
(Tammela et al., 2008). Upon binding to its ligands VEGF-C or VEGF-D, 
VEGFR-3 plays an important role in lymphangiogenesis but is not important 
for angiogenesis (Deng et al., 2015; Zhang et al., 2010).  In this sense, 
transgenic mouse models harbouring mutant forms of VEGFR-3 (ligand 
binding domain/ tyrosine kinase domain) showed disrupted lymphatic growth 
but normal blood vessel development (Zhang et al., 2010). Moreover, VEGF-
C binding onto VEGFR-3 has been reported to regulate several downstream 
signalling pathways that are important in embryonic or post-natal 
lymphangiogenesis, further highlighting the major role of VEGFR-3 in 




Since VEGFR-2 is one of the major receptors involved in angiogenesis, I will 
focus on signalling pathways mediated by VEGF-A/VEGFR-2. 
1.7 VEGFR2-ACTIVATED SIGNALLING IN ANGIOGENESIS 
VEGFR-2 undergoes auto-phosphorylation upon binding to VEGF-A and 
leads to activation of downstream signalling pathways that mediate 
angiogenesis and cell survival (Abhinand et al., 2016). Some of the most 
important signalling pathways activated by the VEGF-A/VEGFR-2 axis is: 
Extracellular Signal-Regulated Kinase (Erk) pathway, the p38 Mitogen-
Activated Protein Kinase (MAPK) pathway, activation of phospholipase C, the 
phosphatidylinositol 3-kinase/Akt pathway, the calcineurin/Nuclear Factor of 
Activated T-cells (NFAT) pathway and the Notch signalling pathway. 
1.7.1 EXTRACELLULAR SIGNAL-REGULATED KINASE (ERK) PATHWAY 
Activation of the Mitogen activated protein kinase (MAPK) signalling by VEGF-
A plays a major role in EC proliferation, differentiation, and cell survival (Yoon 
and Seger, 2006). When VEGF binds to VEGFR-2, the intracellular kinase 
domain of the receptor get phosphorylated. Then, an adapter protein called 
GRB-2 (having SH2 binding domain) interacts with the phosphorylated 
tyrosine kinase domain of the intracellular domain of the VEGF receptor. GRB-
2 recruits SOS, which is a guanine nucleotide exchange factor (GEF). SOS 
contains an allosteric binding pocket which binds Ras GTP and induces a 
conformational change that activates GEF activity in SOS (Jun et al., 2013). 
SOS then removes GDP from membrane bound Ras which becomes 
activated and can initiate a cascade of phosphorylation events by 




KK MEK1/2, which finally will activate MAPK ERK1/2 (Thatcher, 2010). The 
Ras/Raf/MEK, ERK pathway regulates important events in endothelial cell 
angiogenesis by controlling the activation status of a number of transcription 
factors including c-myc, CREB, c-FOS, ATF2, etc which play pivotal roles in 
the onset/progression of angiogenesis (Armesilla et al., 1999; Fearnley et al., 
2014; Srinivasan et al., 2009).  Underlying the important role of this pathway 
in pro-angiogenic processes, it has been reported that targeted deletion of the 
Ras pathway shows defective Erk 1/2 which is important in proliferation and 
migration in ECs in mouse embryo (Srinivasan et al., 2009).  
1.7.2 P38 MITOGEN ACTIVATED PROTEIN KINASE 
The p38 MAPK family consists of four isoforms; p38-α, -β, -γ, and -δ encoded 
by four different genes (Corre et al., 2017). p38β is found in the brain, p38γ is 
expressed in skeletal muscles, and p38δ is found in the pancreas, kidneys, 
testis, and small intestines.  p38α/MAPK14 is ubiquitously expressed and is 
simply referred to as p38 (38 kDa) (Corre et al., 2017). p38 becomes 
phosphorylated by an upstream MAPKK called MEK3/6. They are 
heterogeneously expressed at different levels throughout all human tissues 
(Corre et al., 2017). Targeting Y1214 residue within the VEGFR-2 tyrosine 
kinase domain can specifically inhibit p38 activation indicating that 
phosphorylation of VEGFR-2 at that amino acid plays a critical role in the 
subsequent molecular events that lead to VEGF-mediated activation of the 
p38 pathway in endothelial cells (Corre et al., 2017). Several studies have 
showed the role of p38 in regulating hypoxia, angiogenesis and notably its 
importance in migration of endothelial cells via VEGFR-2 signalling (Corre et 




p38 mediated signalling pathway is essential for HIF1 and VEGFA-165 
expression. VEGFA-165 on binding to its receptor VEGFR2 results in a series 
of downstream phosphorylation mechanisms via VEGFR2-
Nck/p38/MK2/HSP27 which leads to actin remodelling into stress fibres 
contributing to cell migration (Corre et al., 2017; Yoshizuka et al., 2012). p38 
is thought to regulate the ECM degradation by regulating the proteolytic 
activity of metalloproteases (MMP9 and MMP2/uPA) which also implicates the 
p38 pathway as a regulator of angiogenesis (Corre et al., 2017). 
1.7.3 PHOSPHATIDYLINOSITOL-3 KINASE (PI3K) PATHWAY 
Phosphoinositide 3-kinases (PI3Ks) are lipid kinases that transduce 
intracellular signals implicated in the regulation of various cellular functions 
including cell proliferation, adhesion, migration, survival, and angiogenesis 
(Graupera et al., 2008). This pathway plays an essential role in the formation 
of normal blood vessels during development. There are three classes (I, II and 
III) of PI3K proteins that have been identified. Class IA PI3K isoform has p110 
catalytic subunits namely p110α, p110β, p110γ or p110δ (Graupera et al., 
2008; Soler et al., 2013). p110α and p110β are ubiquitously expressed and 
p110γ is expressed majorly in leucocytes. P110α is highly expressed in ECs 
when stimulated by VEGF-A (Graupera et al., 2008).  Mouse embryos lacking 
p110α catalytic subunit develop vascular defects, indicating that this subunit 
is essential for EC migration and angiogenesis (Graupera et al., 2008; Karar 
and Maity, 2011). Inhibition of p110α reduced the viability of tumor associated 
ECs serving as an excellent therapeutic target (Soler et al., 2013). Transgenic 
mouse models lacking p110α subunit showed that this subunit is required in a 




survival (Graupera et al., 2008).  Activation of PI3K/AKT pathway increases 
VEGF secretion in cancer cells and also modulates the expression of NO and 
angiopoietins (Soler et al., 2013; Karar and Maity, 2011). Thus, PI3K pathway 
is important in both physiological and pathological blood vessel formation. 
Three members have been identified in class II- P13KC2α, Pl3KC2β, and 
P13KC2γ, while Class III contains only one member- VpS34 (Fruman et al., 
1998). Although a possible role of PI3KC2α in blood vessel formation has 
been predicted in knockout mouse models, their downstream effector 
pathways have not been clearly studied (Yoshioka et al., 2012). Mutagenic 
studies of class III VpS34 PI3Ks have not associated this kinase with human 
diseases but have shown that it is predominantly involved in membrane 
trafficking functions and thus this enzyme is of less relevance to angiogenesis 
(Jean and Kiger, 2014). 
P110α is an interesting target to treat occlusive vascular disease, like bypass 
graft stenosis or restenosis, which is characterised by migration and 
proliferation of Vascular Smooth Muscle cells (VSMC) induced by growth 
factors (Scherner et al., 2011). By blocking or inhibiting the activity of p110α 
or p110β using siRNA or VSMC specific deletion, Scherner et al, 2011 have 
demonstrated that p110α but not p110β is crucial for growth factor-induced 
proliferation and migration of VSMC in vitro and in vivo (Scherner et al., 2011).  
Exercise induced hypertrophy is thought to be cardioprotective due to increase 
in cardiac output whereas pathological hypertrophy leads to serious 
irreversible complications (Weeks et al., 2012). It was identified that activation 
of phosphoinositide 3-kinase p110α (PI3K(p110α)) is important in regulating 




phosphorylation of downstream signalling proteins. Study by Lin et al, 2010 
showed a declined cardiac function in dominant negative PI3K(p110α) 
(dnPI3K) with myocardial infarction (MI) when compared to Ntg (non-
transgenic) mice with MI. GRB14 is an adapter protein which is expressed 
more in the heart compared to other tissues, negatively regulates insulin 
receptor and FGFR-1 making it an interesting target (Lin et al., 2010). Akt 
activation was reduced in GRB14 KO models and dnPI3K models in the heart 
making the animal more susceptible to myocardial infarction. Increased 
activity of PI3K is directly involved in maintaining fatty acid oxidation and Akt 
activation thereby protecting the heart against cardiac dysfunction (Lin et al., 
2010) 
Weeks et al., 2012 showed that dnPI3K mouse with attenuated PI3K levels 
showed faster disease progression and increased mortality rate in models of 
MI. Increase activity of PI3K in constitutively active phosphoinositide 3-kinase 
(caPI3K) models showed better cardiac function (Weeks et al., 2012). HSP70 
(Heat shock protein 70) had previously shown to protect the heart under 
stress. An interesting observation of increase in Akt activity was found in 
models of caPI3K when HSP70 was knocked out when compared with caPI3K 
under basal conditions. However, transgenic overexpression of HSP70 in 
dnPI3K mouse did not rescue the hypertrophic response. These results 
demonstrated that PI3K(p110α) protected the heart independently of HSP70 
(Weeks et al., 2012). Genes related to exercise-induced protection of the heart 
where mimicked in caPI3K models with enhanced PI3K(p110α) activity 
(Weeks et al., 2012). rAAV6-caPI3K (recombinant adeno-associated viral 6-




the cardiomyocytes showed restoration of cardiac function in TAC (Transverse 
aortic constriction) mouse models, 4 weeks post vector delivery demonstrating 
increased Akt activation when compared to control vector-TAC mouse (Weeks 
et al., 2012). 
PI3K(p110α) induces tumorigenic properties in other cell types (Weeks et al., 
2012). Silencing or blocking the activity of p110α using selective inhibitors in 
several small cell lung cancer (SCLC) cell lines results in increased cell 
apoptosis and activation of Akt and phosphorylation of mTOR targets (Wojtalla 
et al., 2013). Furthermore, angiogenesis experiments performed in the chick 
embryo chorioallantoic membrane (CAM) showed that p110α inhibition 
impaired SCLC tumor formation and vascularization in vivo suggesting that 
pharmacological inhibition of p110α stands as an excellent therapeutic target 
to treat tumor progression (Wojtalla et al., 2013).  
Evidence from literature shows that there are several signalling pathways that 
regulate tumorigenesis and survival of cardiomyocytes (Cheng & Force, 
2010). SF-1126 and XL765 inhibitors are given to block the activity of 
PI3K(p110α) in cancer cells but as we saw in this section, p110α is essential 
in restoring physiological heart growth and protection from pathological stress. 
Therefore, targeted delivery of anti-p110α specifically to cancer cells without 
causing any effect in the heart, is gaining attention (Cheng & Force, 2010). 
1.7.4 PROTEIN KINASE C 
PKC signalling enhances angiogenic activity in endothelial cells induced by 
VEGF stimulation. It belongs to a family of serine/threonine kinases grouped 




and βII), novel PKC (nPKC) (ẟ, Ꜫ, η /L, Ө), and atypical PKC (aPKC) (η, ι/λ). 
Inhibition of PKCα in HUVECs inhibits vessel formation in in vitro studies and 
myocardial neovascularization in in vivo models in mice (Xu et al., 2008).  As 
we see an increase in evidence of VEGF in maintaining vascular homeostasis, 
this positive feedback loop is an important feature in regulating angiogenesis 
(Xu et al., 2008). It has been demonstrated that PKC promotes angiogenesis 
via VEGF induction in the ECs via VEGF/VEGFR2 signalling. VEGF mRNA 
levels were upregulated when they were subjected to PKC activation by 
Phorbol-12-myristate-13-acetate (PMA) (Xu et al., 2008). Interestingly the 
reverse effect was also observed with VEGF activating PKCα in HUVECs. 
Thus, an autocrine feedback loop is demonstrated where PKC enhances 
VEGF production which in turn acts like a positive feedback loop activating the 
PKCs in ECs promoting angiogenesis (Xu et al., 2008). 
1.7.5 CALCINEURIN/NFAT PATHWAY 
Calcineurin (CaN) (80kDa) is a heterodimeric protein composed of two sub-
units; calcineurin A (a catalytic subunit) and calcineurin B (a regulatory 
calcium-binding subunit) of approximately 60 kDa and 20 kDa respectively. It 
is a calcium and calmodulin-dependent serine/threonine phosphatase. There 
are three isoforms of calcineurin A (α, β, γ), encoded by three different genes 
(Klee et al., 1998). The isoforms α and β are distributed throughout the body, 
while γ is majorly distributed in the brain and testis (Kung et al., 2001). The 
calcium dependent activity of calcineurin is regulated by calmodulin (CaM). 
The enzyme is activated upon calmodulin binding to calcineurin’s active sites. 
This activation is dependent on the Ca2+ concentrations within the cell. The 




1998). Increase in intracellular Ca2+ concentration results in 
dephosphorylation of the best characterized substrate of CaN the transcription 
factor nuclear factor of activated T-cells (NFAT) which is then translocated into 
the nucleus (Armesilla et al., 1999). NFAT belongs to a family of transcription 
factors (NFATp (NFAT1), NFATc (NFAT2), NFAT3, and NFAT4) which is 
involved in the activation of genes important in angiogenesis or inflammatory 
immune responses. VEGF has been reported to induce the intracellular Ca2+ 
concentrations which then activate the CaN/NFAT pathway in endothelial cells 
(Armesilla et al., 1999). Inhibition of CaN activity with Cyclosporin A (CsA), as 
an Immunosuppressive drug identified as a strong inhibitor of calcineurin, had 
been reported to inhibit VEGF-induced angiogenic process in vitro and in vivo 
(Hernandez et al., 2001). These studies demonstrate the relevance of the 
CaN/NFAT pathway in the regulation of angiogenesis and highlight the 
potential of manipulating CaN activity to therapeutically modulate angiogenic 
processes. 
1.8 NOTCH SIGNALLING PATHWAY 
Notch signalling is a tightly regulated pathway which controls cell fate 
specification, growth, differentiation, and cell death in many organisms (Bray, 
2006). Notch receptors are transmembrane proteins which undergo 
glycosylation within the endoplasmic reticulum involving the enzyme Protein 
O-fucosyl transferase (POFUT-1) (Roca et al., 2007). The pre-protein is then 
processed in the trans-Golgi network by a protease called furin resulting in a 
molecule with a non-covalently linked extracellular domain (NECD) and a 
notch intracellular domain (NICD) subunit (Roca et al., 2007). The NECD is 




NICD is made up of 6 tandem ankyrin repeats, glutamine rich domain and a 
PEST sequence in its C-terminal region (Roca et al., 2007). (Figure 1.8.i). Four 
Notch receptors have been identified (Notch1–4) in mammals which can 
interact with five ligands, namely Delta-like ligand 1, Delta-like ligand 3, Delta-
like ligand 4, Jagged1, and Jagged2 (Hofmann et al., 2007). The ligands are 
collectively referred to as DSL (Delta/Serrate/Lag-2) and containing an 
extracellular N-terminal DSL motif that binds to the receptor, followed by a 
variable number of EGF-like repeats (Figure 1.8.i). In the cytoplasmic region 
the only feature of Notch ligands is the presence of a C-terminal PDZ binding 
domain (Roca et al., 2007). 
1.8.1 MECHANISM OF NOTCH SIGNALLING 
Notch signalling takes place between two cells which possess ligand or 
receptor on different cells (trans) and inhibition occurs when the ligand and 
receptor are present on neighbouring cell (cis) (Kopan, 2012) (Figure 1.8.i). 
Ubiquitination of notch ligand occurs with the help of a protein ligase called 
the E3 ubiquitin. This protein interacts with the notch ligand as well as E2 
ubiquitin-conjugated enzyme, aiding in transfer of ubiquitin onto the notch 
ligand. (Dutta et al., 2021, Kopan, 2012). Upon binding of ligand to its receptor, 
the juxtamembrane negative control region (NRR) recruits ADAM10 which 
cleaves the receptor at the S2 site. The ubiquitin catalyzes lysosomal 
endocytosis of the ADAM10 cleaved notch ligand-notch ECD receptor 
complex. Further cleavage in site S3 occurs with the help of γ-secretase, and 
results in the release of the NICD (Kopan, 2012). Interestingly, two distinct 
types of cleavage at the S3 site have been identified in Notch1 after activation.  




a strong transcription regulation (Tagami et al., 2008). Whereas S3-S or S3-L 
with serine/leucine terminus generates unstable NICD resulting in a weaker 
intracellular signal (Tagami et al., 2008). The NICD translocates into the 
nucleus and binds to a nuclear adaptor protein called CSL (CBF-1/RBPJ-κ, 
Su(H), Lag-1) along with other proteins like histone deacetylases (HDACs) or 
Histone acetyltransferases (HATs) either causing suppression or activation of 
the chromatin conformation. Nuclear NICD also recruits other components of 
the transcription machinery such as mastermind like (MAML) and p300 
(Kopan, 2012). Transcriptional activation involves phosphorylation of NICD 
within its PEST domain by kinases such as the cyclin-dependent kinase 8 
(CDK8) kinase (Kopan, 2012). This process triggers transcription of notch 
target genes like Hairy/Enhancer of Split (Hes) and Hes related proteins (Hey), 
basic helix-loop-helix (bHLH) which further upregulate the expression of 





Figure 1.8.i Cellular events involved in Notch Signalling. Angiogenic 
signal sending cell possess the notch ligand. Cell receiving the angiogenic 
signal possess notch receptor. Upon recruitment of ubiquitin by E3 ubiquitin 
ligase, the Notch ligand binds to the notch extracellular domain (NECD). The 
notch receptor is processed by a metalloprotease called ADAM10 which 
releases the Notch ligand-receptor ligated complex and is trans endocytosed 
into the ligand presenting cell. γ Secretase cleaves the notch intracellular 
domain (NICD) which is released into the cell. It is then translocated into the 
nucleus and transcribes genes which are important in cell proliferation and 
migration. Notch receptor domain showed in yellow are EGF-like repeats, 
some of them shown in blue are involved in ligand binding, Notch/LIN-12 
domains (purple), single transmembrane domain, ankyrin repeat domain 
(blue) and PEST domain (black) in the C-terminal. Ligand domains shown are 
EGF-like repeats (yellow), transmembrane region, and an additional feature 
called von Williebrand factor (vWF) (red) is present in Jag/Ser ligand in its C-
terminal. (Adapted from Roca C., & Adams R. H., 2007); Phng L.-K., & 




1.8.2 NOTCH SIGNALLING AND ENDOTHELIAL CELL SPECIFICATION 
Notch signalling controls multiple aspects of endothelial cell specification 
depending on their position and location in the vascular beds (Phng and 
Gerhardt, 2009).  The signalling between DLL4/Notch in the endothelial cells 
direct towards arterial or venous phenotype. Targeted deletion of Notch-
related genes in mouse or in zebrafish showed deformed arteries and veins in 
the mutant animals (Napp et al., 2012; Siekmann and Lawson, 2007). ECs 
stimulated by VEGF-A compete for the tip cell position via DLL4/Notch 
signalling (Phng and Gerhardt, 2009).  Heterozygous deletion of dll4+/- in a 
mouse model produced excessive filopodial extension in the presence of 
VEGF signalling (Suchting et al., 2007).  Decreased expression of VEGFR1 
and increased expression of VEGFR2 was detected in dll4+/- mice suggesting 
that VEGF signalling in Notch-signalling is involved in the regulation of tip cell 
proliferation and migration (Suchting et al., 2007). DLL4 has therefore been 
identified as a negative regulator of vessel sprouting and branching (Suchting 
et al., 2007). The cell that produces more DLL4 becomes the tip cell (Phng 
and Gerhardt, 2009). In the presence of VEGF, endothelial tip cells promote 
lateral inhibition between the neighbouring cells and creates a non-uniform 
population. The stalk cells receive more notch signal and undergo 
transcriptional repression of VEGF receptors Kdr, Nrp-1, Flt4 while stimulating 
decoy receptor s(Flt-1) (Phng and Gerhardt, 2009). Regulation of VEGF-
activated intracellular signaling in endothelial cells is regulated by a plethora 
of cellular proteins. Among these regulators, our laboratory has recently 
identified an important role for the Plasma Membrane Calcium ATPase 4 




endothelial cells. Given the relevance of this work for my project, the features 
of PMCA and its role in angiogenesis are described in detail in this 
introduction.     
1.9 PLASMA MEMBRANE CALCIUM ATPase PUMP (PMCA) 
PMCAs is a member of P-type ATPase family which is characterised by 
formation of aspartyl phosphate intermediate during its functional cycle. It has 
high affinity to bind Ca2+ ions but has lower extrusion capacity when compared 
to the sarcoendoplasmic reticulum (SERCA) pumps (Stafford et al., 2017; 
Strehler and Zacharias, 2001). It releases one Ca2+ ion from intracellular 
cytosol to the extracellular space for every ATP hydrolysed. PMCA extrudes 
Ca2+ to avoid cytotoxic overload which may lead to apoptosis and cell death 
(Bruce., 2018). In mammals, there are 4 different isoforms of PMCA (PMCA1-
4). All of them transport Ca2+ to the extracellular space but their affinity for 
calcium varies between the different isoforms. 
1.9.1 STRUCTURE OF PMCA 
Like other types of P-type ATPase pumps, all isoforms of PMCA consist of 
hydrophobic transmembrane domains flanked by -NH2 and -COOH 
cytoplasmic tails. The putative structure of PMCAs based on their sequence 
is illustrated in Figure 1.9.i. PMCAs intracellular domain contains 80-90 amino 
acids. In addition to the cytoplasmic ends, PMCAs have two large intracellular 
loops spanning transmembrane domains 2-3, known as “transducer domain”, 
and 4-5, which corresponds to the catalytic domain. The catalytic domain 
contains an autoinhibitory region regulated by interaction with a calmodulin 




terminal domain and the catalytic loop of the pump renders an open or closed 
conformation in the presence or absence of Ca2+-calmodulin complexes, and 
thus regulates the activity of the pump. RNA splicing in the N-and C-terminal 
regions gives rise to more than 20 splice variants (Stafford et al., 2017). 
Figure 1.9.i Diagrammatic illustration of P-type Plasma membrane Calcium 
transport ATPase pump. The Ca2+ transport pumps possess 10 
transmembrane domains connected by 5 extracellular loops, 2 intracellular 
loops (loop connecting transmembrane domain 4 and 5 contains the catalytic 
domain with ATP binding site), and N- and C-terminal ends flanking either end 
of the pump inside the cell. Various interacting partners of the pump are 
shown. (Figure adapted from Stafford N et al., 2017). CAM-BD, calmodulin 
binding domain; PDZ-BD, domain binding to protein PDZ-domains. 
 
1.9.2 PMCA BINDING DOMAINS 
PDZ binding domains: These binding domains are located at the end of the 
C-terminal tail. PDZ binding domain derives its name from the originally 
identified conserved sequence elements contained within postsynaptic 
density protein PSD95/SAP90, Drosophila tumor suppressor protein dlg-A, 
and tight junction protein ZO-1 (Fanning and Anderson, 1999). These domains 
possess amino acid residues which serves as a scaffold for protein 




partner proteins, such as members of the membrane-associated guanylate 
kinase (MAGUK) family, neuronal nitric oxide synthase (nNOS), 
calcium/calmodulin-dependent serine protein kinase (CASK), Ania3, C-
terminal LIM domain protein (CLP36), PMCA-interacting single-PDZ domain 
(PISP), etc (Stafford et al., 2017; Strehler and Zacharias, 2001). 
Calmodulin binding site: A calmodulin binding domain is located at the C-
terminal intracellular domain above the PDZ binding site. The auto-inhibitory 
function of the pump is regulated by binding of the complex Ca2+-calmodulin 
to this domain. The calmodulin binding domain binds to the second and the 
third intracellular domains of the pump generating a closed, inactive version. 
Increments in the concentration of cytoplasmic Ca2+ leads to the formation of 
active Ca2+-calmodulin complexes that bind to the CAM-BD of the pump 
releasing the interaction between the intracellular domains and freeing the 
pump from auto-inhibition (Oceandy et al., 2011).   
1.9.3 PMCA AS A REGULATOR OF INTRACELLULAR SIGNALLING 
PATHWAY VIA INTERACTION WITH PARTNER PROTEINS 
PMCA is a Ca2+ dependent regulator of signal transduction pathways which 
functions by complex protein interactions. Some of the interacting protein 
families are common to all isoforms of PMCA whereas a few are specific. 
PMCA serves as a scaffold protein which anchors many interacting proteins 
at the plasma membrane (Stafford et al., 2017). Recent studies show that, 
PMCA interacts and inhibits the activity of Ca2+/calmodulin dependent 
proteins. Some of the identified functions of PMCA include organizing and 
regulation of Ca2+ efflux, modulation of NO signalling, or acting as a structural 




example, as described in the paper by Stafford et al., 2017, PMCA4b-nNOS 
interaction has shown to play a pivotal role in excitable cells like neuronal cells, 
cardiac and smooth muscle cells. Neuronal NOS-I deficiency had shown 
reduced susceptibility to cerebral ischemia in mouse models (Huang et al., 
1994). Scuh et al., 2001 demonstrated that PMCA4b is a negative regulator 
of nitric oxide synthase I (NOS-I). The interaction is initiated by binding of -
COOH terminal of PMCA4b and PDZ domain of NOS-I. Cytoskeletal protein 
called α1-syntrophin forms a ternary complex with PMCA and nNOS and binds 
at the catalytic intracellular loop of PMCA and inhibits Ca2+/calmodulin enzyme 
dependent synthesis of NO in the heart (Stafford et al., 2017). Tumor 
suppressor Ras-associated factor 1 (RASSF1) was also found to interact with 
the second intracellular loop of PMCA which has same binding domain as that 
of α1-syntrophin. Thus, PMCA regulates the EGF dependent activation of 
ERK signalling pathway. Upon binding to RASSF1, the cell survival pathway 
is inhibited therefore PMCA has a role in cellular apoptosis (Armesilla et al., 
2004). Previous studies established that PMCA negatively regulates the 
endothelial nitric oxide synthase (eNOS) via its interaction with the catalytic 
domain of the pump (Holton et al., 2010). Disruption of the PMCA-eNOS 
interaction showed a reduction of phosphorylation of Thr-495 of eNOS thus 
suggesting a negative regulatory activity. PMCA 2 and 4 had been reported to 
bind with eNOS at the same binding region of the catalytic domain as in the 
case of Calcineurin A (Holton et al., 2010). Increase in intracellular Ca2+ levels 
lead to activation of PMCA which in turn functions by extruding calcium into 
the extracellular region. This creates a low calcium microdomain which 




Isoform Ꜫ of the trafficking protein 14-3-3 interacts with NH2-tail region of 
PMCA4. 
1.9.4 CA2+ TRANSPORTATION VIA PMCA PUMP 
Calcium transportation via the PMCA takes place in two conformational states 
namely E1 and E2. E1 state has high affinity for Ca2+ binding whereas E2 
phase has low affinity (Mangialavori et al., 2013) In the E1 state, the pump 
exists in a conformation state exposing the high affinity sites for calcium 
binding within the cellular cytosol. Upon binding of calcium onto the 
intracellular catalytic domain, the protein undergoes phosphorylation by 
hydrolysis of ATP. ATP can bind to the protein even in the absence of Ca2+ 
but cannot affect the reaction cycle. Ca2+ is essential for conformational 
transition within the transmembrane helices (Mangialavori et al., 2013). The 
pump then exists in E1-P unstable conformation state. Mg2+ ion stabilizes this 
unstable state into E2-P stable intermediate. This configuration displays Ca2+ 
outside the cell effecting the release into the extracellular region. 
Dephosphorylation of E2-P phase renders a stable inactive E1 configuration 
with high Ca2+ binding affinity (Mangialavori et al., 2013). 
1.9.5 PMCA ISOFORMS AND THEIR TISSUE DISTRIBUTION 
Alternative splicing at the amino (N) terminal of pre-mRNA of PMCA gives rise 
to x or z splice variant and splicing at carboxy (C) terminal gives rise to a, b, 
or d variants (Strehler and Zacharias, 2001). There are four known isoforms 
of PMCAs which are encoded by different genes ATP2B1-4. In human and 
mouse models, PMCAs are differentially distributed and have functional 
diversity in different cell types. PMCA1 and PMCA4 are ubiquitously 




(Strehler and Zacharias, 2001; Faddy et al., 2008). Interestingly, the 
accumulation of specific isoforms within specialized type of cells was 
explained by Zacharias and Strehler in a study on neuronal maturation 
directed by transcriptional regulation of Ca2+ ions (Zacharias and Strehler, 
1996).  Thus, the regulation of PMCA expression is critical for cell survival 
which is directly proportional to Ca2+ activity (Brini and Carafoli, 2011). 
1.9.5.a PMCA1 
 
PMCA1 is a member of the P‐type ATPase transport pump, which actively 
extrude Ca2+ ions into the extracellular space from cytosol. It is encoded by 
the gene ATP2B1 in human and is important in maintaining Ca2+ homeostasis 
and blood pressure (Kobayashi et al., 2012). PMCA1 has been described as 
an important housekeeping gene. Embryonic lethality was observed in 
homozygous global knockout of Atp2b1 (Okunade et al., 2004). PMCA1 has 
an important role in maintaining blood pressure (BP) as verified in tissue-
specific gene ablation studies in mice (Kobayashi et al., 2012). Specific 
ablation of Atp2b1 in vascular smooth muscle cell (VMSC) leads to higher 
systolic BP in KO animals. Intracellular calcium concentration in VSMC of KO 
animals was significantly increased both basal and phenylephrine-stimulated 
conditions highlighting the relevance of PMCA1 in the regulation of 
intracellular calcium levels (Kobayashi et al., 2012). Interestingly, PMCA1+/- 
knockout mice did not show major alterations in BP at 6 months of age, 
however, increments in BP were observed in aging animals in association with 
arterial remodelling (Little et al., 2017). The importance of PMCA1 as a 








PMCA2, is an important Ca2+ transporter protein critical for the clearance of 
calcium from excitable cells. A high level of PMCA2 is identified in neuronal 
cells, cochlear outer hair cells, and mammary cells (Empson et al., 2010; 
Kozel et al., 1998; VanHouten et al., 2010). Aberrant expression of PMCA2 
results in severe neuronal damage due to the lack of calcium homeostasis and 
is closely associated with aging and sensitivity to inflammation (Boczek et al., 
2019). Homozygous deletion of Atp2b2 showed growth impairment when 
compared with heterozygous or wildtype mouse models with additional 
impairment in motor functions. (Kozel et al., 1998). Heterozygous loss of 
Atp2b2 in mouse shows progressive high frequency hearing impairment 
whereas homozygous Atp2b2 null mutants are completely deaf (Smits et al., 
2019).  In mammary epithelial cells, loss of PMCA2 due to weaning after 
lactation shows sensitisation towards apoptosis by increasing intracellular 
Ca2+ levels (VanHouten et al., 2010). On the other hand, overexpression of 
PMCA2 causes breast cancer due to resistance towards apoptosis 
(VanHouten et al., 2010). Overall, PMCA2 plays a role in calcium 
transportation involved in maintaining homeostatic balance, hearing, 
protecting the cells from calcium toxicity and apoptosis. 
1.9.5.c PMCA3 
 
In contrast to other isoforms of PMCAs, PMCA3 has a more restricted tissue 
distribution to specific neurons like cerebellar parallel fiber-Purkinje neuron 




sensory neuronal communication disorders but has not been extensively 
studied so far (Strehler, 2013; Strehler and Thayer, 2018).  
1.9.5.d PMCA4  
 
PMCA4 is ubiquitously expressed in all cell types. Among the two splice 
variants “a” and “b”, originated by alternative splicing in the C-terminal end, 
the sperm tail principally expresses “a” splice form whereas “b” splice variant 
is the major isoform expressed in cardiomyocytes, endothelial cells, pancreas, 
and epithelium (Padanyi et al., 2016). Studies using genetic alteration of 
PMCA4 expression in animal models are starting to elucidate the involvement 
of PMCA4 in the pathophysiology of several diseases. The first analyses of 
Atp2b4-/- showed that mice lacking Pmca4 were viable (Schuh et al., 2004). 
Pmca4 null animals showed infertility in male due to reduction in sperm motility 
(Schuh et al., 2004). Further studies using animal models with altered 
expression of PMCA4 have revealed that deregulation in PMCA4 expression 
is linked to cardiac pathologies. In a study by Wu et al.,2009 it has been shown 
that the overexpression of PMCA4b splice variant antagonizes cardiac 
hypertrophy due to pressure overload by transverse aortic constriction or 
neuroendocrine agonist phenylephrine/Ang II (PE/Ang II) stimulation (Wu et 
al., 2009). Prasad et al., in their work showed that a double mutant mouse 
model generated by crossing transgenic mutant (Glu180Gly) α-tropomyosin 
(Tm180) and a PMCA4 KO had a protective role in cardiac hypertrophy by 
diminishing its calcineurin activity and showed reduced expression of L-type 
Ca2+ ion channels. Tm180 mutation is a commonly observed cardiac 
hypertrophic mutation which causes increase in Ca2+ sensitivity leading to 




fibrotic genes like collagen 1a1 (Col1a1) and connective tissue growth factor 
(Ctgf), increase in expression of calcineurin A (CnA) and Rcan1 are commonly 
observed in Tm180 related hypertrophy. It has been well established in 
previous studies that PMCA4 inhibits NO production. Loss of PMCA4 leads to 
increase in localized Ca2+ concentration and leads to activation of NOS. The 
increase in NO availability thus leads to the activation of cGMP-PKG signalling 
which is associated with prevention of pathological hypertrophy (Prasad et al., 
2014). Mohamed et al., 2016 demonstrated that fibroblast specific KO of 
PMCA4 reduced cardiac hypertrophy by producing high levels of secreted 
frizzled related protein 2 (sFRP2) whereas cardiomyocyte directed KO did not 
show any protective response (Mohamed et al., 2016). Systemic deletion of 
PMCA4 attenuated the hypertrophic response in the heart when the KO 
mouse was subjected to transverse aortic constriction (TAC) for 5 weeks 
inducing cardiac pressure overload (Mohamed et al., 2016). Treatment with 
aurintricarboxylic acid (ATA) reversed cardiac hypertrophy (Mohamed et al., 
2016). As described previously, PMCA4 directly interacts with neuronal nitric 
oxide synthase nNOS and regulates NO-dependent cardiac signal 
transduction pathways in cardiomyocytes. This was studied in global depletion 
models of PMCA4 (PMCA4 KO) versus acute inhibition of PMCA4 using aurin 
tricarboxylic acid (ATA) (Lewis et al., 2018). Global ablation of PMCA4 does 
not alter BP, arterial structure, or arterial contractility but acute inhibition of 
PMCA4 using ATA showed nNOS dependent reduction in BP and arterial 






1.9.6 ROLE OF PMCA4 AS AN INHIBITOR OF VEGF-INDUCED 
ANGIOGENESIS 
 
Regarding PMCA4 function in endothelial cells, previous work by our 
laboratory has shown that PMCA4 plays an important role as a negative 
regulator of VEGF-induced angiogenesis via inhibition of the calcineurin/NFAT 
pathway in endothelial cells (Baggot et al., 2014). They demonstrated in their 
work that PMCA4 inhibits VEGF-driven angiogenesis via interaction with 
calcineurin in endothelial cells. The interaction between PMCA4 and 
calcineurin A, at a low calcium microdomain (due to calcium efflux activity) 
impaired the endothelial cell motility and blood vessel formation but not 
endothelial cell proliferation in response to VEGF stimulation (Baggot et al., 
2014). This interaction further revealed the downregulation of NFAT target 
genes RCAN 1.4 and Cox-2. In vivo experiment conducted on Pmca4+/+ or 
Pmca4-/- sham operated non-ischemic legs or femoral ligated ischemic legs 
showed enhanced perfusion of blood flow in Pmca4-/- model at day 5 and 14 
after surgery when compared with WT animals. In the study, it was established 
that the interaction between PMCA4 and calcineurin downregulated the 
calcineurin/NFAT activity and thus served as an endogenous inhibitor of 
VEGF induced angiogenesis (Baggot et al., 2014). 
Following this, our group worked on characterising the effects in angiogenesis 
of a selective inhibitor of PMCA function-aurintricarboxylic acid (ATA) 
previously identified by Mohammed et al., 2013. Kurusamy et al., 2017 
reported that the inhibition of PMCA4 activity by ATA lead to enhanced VEGF-
mediated endothelial cell motility and blood vessel formation by releasing the 




nitric oxide with an increase in interaction between PMCA4 and eNOS in 
endothelial cells (Kurusamy et al., 2017). No side effects were observed at 
nanomolar levels of ATA, however, increasing micromolar concentration, 
resulted in embryonic toxicity in endothelial cell cultures and zebrafish in vivo 
models (Kurusamy et al., 2017). Having focused on the functional relevance 
of the ion transport pump, the molecular mechanisms underlying PMCA4 
regulation of VEGF-activated signalling pathways in endothelial cells were 















































Therapeutic angiogenesis has gained attention since the discovery of pro-
angiogenic factor VEGF (Zachary et al., 2011). However, therapeutic 
strategies aimed to induce or inhibit blood vessel formation have failed to yield 
clinical benefits for patients suffering from diseases occurring with 
angiogenesis. Therefore, a full understanding of the molecular pathways that 
regulate angiogenesis is an essential pre-requisite to develop more efficient 
therapeutic interventions. It is well established that binding of VEGF-A to 
VEGFR2 leads to an increase in the concentration of cytoplasmic Ca2+ in 
endothelial cells (Brock et al., 1991) that activates intracellular signalling 
pathways such as calcineurin/NFAT, Erk, and others (Armesilla et al., 1999; 
Yoon and Seger, 2006). Previous research in our group revealed endothelial 
PMCA4 as a negative regulator of VEGF driven angiogenesis via inhibition of 
the calcineurin/NFAT pathway (Baggot et al., 2014; Kurusamy et al., 2017). 
However, studies performed in non-endothelial cells have shown that PMCA4 
regulates other transduction pathways, through its interaction with a plethora 
of cytoplasmic partner proteins (Stafford, N. et al., 2017). Therefore, we 
hypothesise that PMCA4 might be regulating several intracellular signalling 
pathways in endothelial cells in its role as a negative modulator of VEGF-
activated angiogenesis. In fact, VEGF-signalling is known to induce the 
expression of genes such as DLL4, extracellular matrix proteins, or cell 
adhesion molecules that play a critical role in the progression of angiogenesis 
(Fish et al., 2017; Liu et al, 2014). However, whether PMCA4 is involved in the 
regulation of these genes in endothelial cells activated with VEGF has not 
been studied so far. Thus, in this project, we would like to test the following 




pathways that are translated into the expression of critical angiogenic 
molecules such as components of the notch signalling pathway, extracellular 
matrix proteins (ECM) or cell adhesion molecules (CAM) in human endothelial 
cells” as illustrated in Fig 2.1. 
 
Figure 2.1. Diagrammatic representation of various pathways involving 
VEGF/VEGFR signalling. Left to right: PMCA4 mediated NO-dependent 
angiogenic pathway regulated by VEGF/VEGFR given in green. CaN/NFAT 
pathway regulated by VEGF/VEGFR is shown in purple. Notch signalling and 
ECM-CAM signalling pathways activated by VEGF/VEGFR are shown in 
orange, gaps in knowledge about the involvement of PMCA4 in the regulation 
of these pathways is denoted by “?”. Extracellular Signal-Regulated Kinase 
(Erk) pathway regulated by VEGF/VEGFR is represented in black. 
 
To this purpose, the following are the objectives established for this project: 
1) To silence the expression of PMCA4 in human endothelial cells by transfecting 
siRNAs targeting PMCA4. 
2) To analyse the effect of PMCA4 downregulation in endothelial cells on the 
VEGF-induced expression of genes related to Notch signalling and encoding 




3) To validate the effects observed in the expression of PMCA4-target genes 
identified above in endothelial cells isolated from large vessels (human 
umbilical vein endothelial cells, HUVEC) or the microvasculature (human 
dermal microvascular endothelial cells, HDMEC) using TaqMan qPCR.  
It has been reported that aging leads to sensitization of cells to apoptosis, 
which disrupts the integrity of endothelial cell wall leading to atherosclerosis. 
Aging impairs NO synthesis and endothelial cell dysfunction (Hoffmann et al., 
2001). As mentioned in section 1.8.5.d, PMCA4 is a negative regulator of NO 
synthesis (Fig 2.1). Thus, we hypothesise that changes in the expression of 
PMCA4, might be involved in decreased NO synthesis during aging. As a first 
step to elucidate the role of PMCA4 in abnormal functioning of EC during 
aging, another objective of my work in a parallel project was: 
4) To investigate whether aging of endothelial cells by high number of tissue 




























3.1 CELLS AND CELL CULTURE 
Early passage Human Umbilical Vein Endothelial Cells (HUVEC) containing 
approximately 500,000 pooled multiple donor viable cells, were purchased 
from Cellworks Ltd., and were cultured in 0.1% gelatin pre-coated plates. 
Endothelial Cell growth media (ECGM, PromoCell, UK) for cell culture was 
supplemented with 1% penicillin/streptomycin/amphotericin B (Sigma-Aldrich) 
and ECGM supplement mix (PromoCell) containing: 2% FBS, 0.4% 
endothelial cell growth supplement, 0.1 ng/mL epidermal growth factor 
(recombinant human), 1 ng/mL basic fibroblast growth factor (recombinant 
human), 90 µg/mL heparin, and 1 µg/mL hydrocortisone). ECGM containing 
supplements will be hereafter referred as ECGM complete. For 
transfection/gene expression experiments HUVEC were used at passages 
(P4-P8) under a controlled aseptic sterile environment. Longer passages were 
required in experiments assessing PMCA4 expression during senescence. 
Human Dermal Microvascular Cells (HDMEC) were purchased from 
PromoCell. Cells were grown in a 0.05% gelatin pre-coated plates in ECGM 
complete. Cell growth was comparatively slower than in HUVEC. Cells were 
used for the experiments at passages (P4-P8). 
3.2 CELL CULTURE IN TISSUE CULTURE FLASKS 
Primary cells were cultured in a small, ventilated flask (T25) immediately after 
purchasing. The flask was first coated with 10 mL of 0.1% gelatin and 
incubated for 15 minutes or more. The cells were suspended in 15 mL of 
ECGM complete media and incubated in a 5% CO2 incubator at 37℃. Once 




detached using 2 mL of Trypsin-EDTA solution (Sigma-Aldrich) to digest the 
cell surface proteins attached to the gelatin-coated flask. Incubation with 
trypsin lasted not longer than two minutes as longer incubation might kill the 
cells. Once the cells were detached, trypsin was neutralised using 8 mL of 
ECGM complete. The cell suspension was then centrifuged at 200g for 5 
minutes. The supernatant was discarded, and the cell pellet was suspended 
in 20 mL of ECGM complete and transferred to a medium flask (T75) that was 
incubated in a 5% CO2 incubator at 37℃ until cells reached confluency. The 
same procedure was repeated to expand cells to a big flask (T175) except 
that the final volume of culture medium was increased to 30 mL. 
3.3 COUNTING AND PLATING CELLS 
Cells were washed with 1X PBS followed by detachment by adding 3 mL of 
trypsin-EDTA solution and incubation for approximately 2 minutes. The flask 
was gently tapped along the sides to completely detach the cells and the 
process was neutralised by adding 8 mL of ECGM complete. The cell 
suspension was centrifuged at 200g for 5 minutes. The cell pellet was 
suspended in 10 mL of ECGM complete after discarding the supernatant 
carefully. A small aliquot of the cell suspension was taken in an empty 
eppendorf and gently mixed-up pipetting and down. The cells were then 
counted using a haemocytometer. The cells are counted from two outer 
opposite squares and the average is calculated. The number of cells per mL 
of cell suspension is calculated according to the following formula: 




The calculated cell count was mixed with required quantity of ECGM complete 
and evenly distributed into the wells. The wells maybe pre-coated with or 
without gelatin prior to the experiment. The plates were incubated under 
controlled conditions of 37°C and 5% CO2 for 24 hours. 
3.4 TRANSFECTION OF PRIMARY ENDOTHELIAL CELLS WITH SMALL 
INTERFERING RNA (siRNA) 
siRNA-mediated knock down of PMCA4 (siRNA-PMCA4) was performed 
using a siRNA targeting specifically human PMCA4; “ON-TARGET-plus 
SMART pool human ATP2B4” (Thermo Scientific). “ON-TARGET-plus non-
targeting pool control duplexes” (Thermo Scientific) (siRNA-NT) was used as 
a control. HUVECs were plated in 6 well gelatin-coated plates (3 ×105 
cells/well) one day prior to transfection. siRNAs were transfected into the cells 
using Lipofectamine 2000 (Thermo Scientific) as following. The plates were 
washed two times with 1X PBS. 5mL of serum free OPTI-MEM was added to 
each well and cells were incubated for one hour at 37℃ and 5% CO2. The 
complexes siRNA-Lipofectamine were prepared by diluting siRNA stocks (20 
µM) in OPTI-MEM according to the indications showed in Table 3.4.a. 
 
Table 3.4.a. Composition of the complexes used in transfection of HUVECs 
(Sol A and Sol B) using siRNA-NT or siRNA-PMCA4. 
 
siRNA-NT 
Sol A 1 Well 7 Wells 
siRNA-NT 4.5µL 31.5µL 
Opti-MEM 245.5µL 1718.5µL 
 
Sol B 1 Well 7 Wells 
Lipofectamine 5µL 35µL 
Opti-MEM 245µL 1715µL 
siRNA-PMCA4 
Sol A 1 Well 7 Wells 
siRNA-PMCA4 4.5µL 31.5µL 
Opti-MEM 245.5µL 1718.5µL 
 
Sol B 1 Well 7 Wells 
Lipofectamine 5µL 35µL 




The contents of solution A and B corresponding to each complex were mixed 
dropwise and incubated for 30 minutes. 500 µL of the complex Lipofectamine-
siRNA were added to each well dropwise while gently swirling. The plates 
were incubated for 6 hours and checked for transfection features. We have 
noticed that after the 6-hours incubation period small, bubble- like vacuoles 
are observed inside the cells (Figure 3.4.i). This is an empirical observation 
that indicates good transfection of the cells with the siRNA. After the 6-hour 
incubation period, the medium containing the transfection solution was 
aspirated and replaced with ECGM complete. The plates were finally 
incubated for 72 hours and then used as required.  
        
Figure 3.4.i. Presence of vacuoles within the cells implies good 
transfection uptake Microscopy image of HUVEC after 6 hours of incubation 
in Opti-MEM containing Lipofectamine-siRNA complexes. Image was 
recorded using a Nikon DSFi1 digital camera coupled to a Nikon ECLIPSE 
TS100 microscope at 10x magnification. Bubble-like vacuoles can be 
observed inside the cells indicating good transfection of the siRNA into the 
cells. 
 
3.5 CELL STIMULATION  
Transfected cells were washed once with 1X PBS and incubating in ECGM 
supplemented only with 1% penicillin/streptomycin/amphotericin B (Sigma-
Aldrich) (hereafter referred as serum-free ECGM). After serum starvation for 





at 25 ng/mL final concentration. Unstimulated cells were used as control. Each 
experimental point was performed in triplicate. The VEGF used in the 
experiments was prepared by dissolving 10 µg of lyophilized VEGF 
(Peprotech) in 400 µL of PBS 1X. 10 µL of this stock solution were added to 5 
mL of culture medium to make a final concentration of VEGF 25 ng/mL. 
3.6 TOTAL RNA ISOLATION 
RNA isolation was performed using a “Total RNA Purification Plus Kit” 
(Norgene) according to the manufacturer’s recommendations. Briefly, the 
media was discarded from the plates and cells were washed with 1X PBS. 
Cells were lysed in 300 µL of RNA lysis buffer. The plates were swirled for 1 
minute to completely lyse the cells. The lysate was collected and stored at -
80℃ or immediately processed as following. The lysate was transferred into 
gDNA Columns provided in the kit and passed throughout the columns by 
centrifugation for 1 minute at 15,600 g. The flow-through was transferred to a 
fresh tube and 200 μL of 100% ethanol was added. The mixture was vortexed 
for 10 seconds and passed throughout RNA purification columns by 
centrifugation at 9,200 g for 1 minute. The flow-through was discarded and the 
columns were washed 3 times with 400 μL of washing buffer by centrifugation 
for 1 minute at 15,600 g. An extra final centrifugation was performed to totally 
eliminate any traces of washing buffer as it contains ethanol. After washing, 
the columns were put into fresh eppendorfs for eluting RNA. 40 μL of RNA 
elution buffer was added, followed by 1 minute of incubation at room 
temperature. The samples were then centrifuged for 2 minutes at 300 g, 




quantified using a NanoDrop 2000 spectrophotometer (Thermo Scientific, UK) 
using elution buffer as blank.  
3.7 REVERSE TRANSCRIPTION 
500 ng of total RNA isolated as described in the previous section were diluted 
in nuclease-free-water to a final volume of 10 μL. A cDNA master mix 
containing the reagents required for the retro-transcription was prepared as 




10x RT Buffer 2.0μL 
25x dNTP mix 0.8μL 
10x RT Random primers 2.0μL 
Multi Scribe reverse 
transcriptase 1.0μL 
RNase inhibitor 1.0μL 
Nuclease free H2O 3.2μL 
Total Per Reaction 10μL 
Table 3.7.a. Composition of the Master mix used for reverse 
transcribing RNA to cDNA 
 
10 μL of cDNA master mix were added to the 10 μL of RNA solution previously 
prepared. The mixture was then briefly centrifuged to eliminate any air 
bubbles. Retro transcription took place in a PTC-200 Peltier thermal cycler, 
according to the following conditions: 25℃ for 10 minutes, 37℃ for 120 
minutes, 85℃ for 5 minutes and 4℃ for until collection. After completion, the 
samples were diluted with 80 μL of nuclease-free water and stored at -80℃ 




3.8 QUANTITATIVE REAL TIME PCR  
A PCR reaction mix was prepared for each primer according to the 







Table 3.8.a. Components of master mix used for TaqMan PCR assays 
A fast optical 96-well reaction plate (Applied Biosystems) was loaded with 14.4 
μL of TaqMan reaction mix and 5.6 μL of cDNA making it up to a final volume 
of 20 μL/well. The plate was sealed with optical adhesive film, centrifuged for 
1 minute at 100 g and loaded into an Applied BioSystem 7500 Fast real time 
PCR system. The machine was setup for amplification programme with 
holding stage at 95℃ for 10 minutes specifically for enzyme activation, 
followed by 40 cycles of denaturization at 95℃ for 15 seconds and 
annealing/extension at 60℃ for 60 seconds. After PCR amplification, the raw 
data was exported to an Excel document to calculate fold change. Ct value or 
the cycle threshold value is a relative measure of concentration of target in a 
PCR reaction. ΔCt value was calculated as the difference between Ct value in 
each sample to the Ct value of the housekeeping gene Hprt-1. ΔΔCt algorithm 
is a method to analyse relative changes in gene expression. It is calculated as 
the difference between ΔCt (treated sample) - ΔCt (untreated sample). 
REAGENTS X1 
TaqMan primer 1.0μL 
TaqMan universal PCR master mix (2X) 10μL 





TaqMan primers used on this study were purchased from Applied Biosystems 
and are indicated in Table 3.8.b. 
TAQMAN PRIMERS ID ASSAY 
Plasma Membrane Calcium ATPase 
Isoform 4 (PMCA4) 
Hs00608066_m1 
Delta like ligand 1 (DLL1) Hs00194509_m1 
Delta like ligand 4 (DLL4) Hs00184092_m1 
c-FOS Hs04194186_s1 
Selectin L (SELL) Hs00174151_m1 
Selectin P (SELP) Hs00927900_m1 
Selectin E (SELE) Hs00174057_m1 
ADAM Metallopeptidase with 
Thrombospondin Type 1 Motif 1 
(ADAMTS1) 
Hs00199608_m1   




transferase 1 (HPRT1) 
Hs99999909_m1 
 
Table 3.8.b. Various TaqMan primers and their gene reference code 
used to run the Applied BioSystem 7500 Fast real-time PCR. 
 
3.9 PROTEIN DETECTION BY WESTERN BLOT 
HUVEC were plated in 6-well tissue culture plates at a density of 250,000 
cells/well. The cells were transfected with siNT or siPMCA4 as described in 
section 2.4. After 72 hours of incubation at 37℃ and 5% CO2, cells were 
lysated in 100 μL of 2X NuPAGE® LDS protein sample buffer (Life Technology, 
UK) containing 0.05% β-mercaptoethanol. The protein lysate was separated 

































Deionised water 7.35mL 
Bis-Acrylamide 2.8mL 
Resolving buffer 3.75mL 




Deionised water 5.45 mL 
Bis-Acrylamide 4.7 mL 
Resolving buffer 3.75 mL 




                                                                                                                                                                          
Composition 
Deionised water 6.1 mL 
Bis-Acrylamide 1.4 mL 
Stacking buffer 2.5 mL 





The components of stacking gel remain always the same, however the 
composition of resolving gel varies across different proteins. PMCA4 has a 
molecular weight of 135 KDa hence a 6% resolving gel was prepared to 
separate the protein bands. Tubulin which was used as loading control has a 
molecular weight of 50 KDa hence requires a 10% resolving gel. The crude 
protein lysate was initially heated at 100℃ for 10 minutes to cleave genomic 
DNA in the samples and facilitate loading into the gel. Just before loading, the 
samples were heated at 100℃ for 2 minutes and cooled on ice. This is an 
essential step as it renders denaturation of the proteins. BLUeye protein 
ladder (GeneFlow, UK) or ProtomarkersTM (National diagnostics) pre-stained 
protein ladder was loaded as markers of protein molecular weight along with 
the samples. PAGE took place in Tris-Glycine buffer Running buffer (0.025M 
Tris, 0.192M Glycine, 0.1% SDS) at 150 volts.  
Once separated by PAGE, proteins were transferred from the gel onto a 
polyvinylidene difluoride (PVDF) membrane using a wet-transfer blotting 
apparatus (Invitrogen). In brief, the PVDF membrane was hydrated in 
methanol for 30 seconds and immediately washed with deionized water to 
remove the methanol from the membrane. The membrane was placed on top 
of the resolving gel inside a “sandwich” formed by several layers of Whatman 
3MM chromatography paper (Sigma-Aldrich, UK) and foam sponges. Transfer 
took place in “Transfer Buffer” (0.025M Tris, 0.192M Glycine, 20% methanol) 
for 90 minutes at 35 volts. The membrane was then incubated in a solution of 
5% semi-skimmed milk in 1X TBS for 1 hour at 4℃ to block unspecific binding 
of primary and secondary antibodies. After blockage, milk solution was 




20) followed by incubation with primary antibody JA3 mouse monoclonal anti-
PMCA4 (Santa Cruz Biotechnology;1:1000) or mouse monoclonal anti-tubulin 
antibody (Sigma; 1:2500) overnight at 4℃. The following morning, membranes 
were washed with TBS-T five times for five minutes and incubated in a 1:5000 
dilution of peroxidase-conjugated sheep anti-mouse immunoglobulin antibody 
in TBS-T for 4 hours. Unbound secondary antibody was removed by washing 
the membrane five times for five minutes with TBS-T. Bound antibodies were 
detected by ECL using an EZ-Chemiluminescence Detection Kit (GeneFlow) 
following the recommendations of the manufacturer. Chemiluminescence 
signal was detected by exposing the membrane to Kodak BioMax MS auto-
radiographic film (Sigma-Aldrich, UK) in dark conditions for different periods 
of time and subsequent development. 
3.10 PCR-BASED SCREENING OF SMALL GENE ARRAYS 
An RT2 ProfilerTM PCR Array Human Notch Signalling Pathway Plus Kit (Ref 
PAHS-059Y) was purchased from Qiagen. Total RNA was isolated from 
HUVEC transfected with siRNA-NT or siRNA-PMCA4 and stimulated with 
VEGF-A (25 ng/mL) for 1 hour, and subsequently retrotranscribed as 
described in previous sections. To screen RT2 ProfilerTM PCR Arrays, a 
reaction mixture was prepared by mixing 100 µL of cDNA with 1350 µL of RT2 
SYBR Green ROX master mix (Qiagen) and 1248 µL of RNase-free water. 25 
µL of this reaction mixture were added into the wells of PAHS-059Y PCR array 
plate (Qiagen) containing primers to detect the expression of 84 genes related 
to the Notch signalling pathway, along with primers for several “housekeeping” 
genes used for normalization. PCR reaction was carried out using an Applied 




10 min at 95℃, followed by 40 cycles of 15 sec at 95℃ and 1 min at 60℃. The 
Ct values obtained in the real time PCR were exported to Excel to calculate 
the fold change. Screening of RT2 ProfilerTM PCR Array Human Extracellular 
Matrix & Cell Adhesion Molecules Kit (Ref PAHS-013Z) (Qiagen) containing 
primers to detect the expression levels of 84 genes encoding proteins related 
to extracellular matrix and cell adhesion molecules, along with primers to 
detect several “housekeeping” genes for normalization purposes, was carried 
as described above except that transfected HUVEC were stimulated with 
VEGF (25 ng/mL) for 3 hours. PCR-based screening of gene array plates was 
performed in three independent experiments. Ct values in obtained in PCR 
reactions performed from HUVEC containing (siNT) or lacking PMCA4 
(siPMCA4) were analysed for statistically significant differences in gene 
expression using the RT2 Profiler PCR Data Analysis facility 
https://dataanalysis2.qiagen.com/pcr according to the instructions of the 
manufacturer (Qiagen). 
3.11 STATISTICAL ANALYSIS 
Results are shown as mean ± SE. Statistical differences between two groups 
were analysed by unpaired, two-tailed Student’s t-test. One-way ANOVA with 
post hoc Tukey’s comparison test was used to analyse differences between 
more than two groups. Samples with more than two groups and two 
independent variables were analysed for statistical significance by two-way 
ANOVA with post-hoc multiple comparison Bonferroni’s test. Statistical 
significance was set at P ≤ 0.05. Experimental biological replicates, indicated 
by ‘n’, are defined as a sample of cells plated in an individual tissue culture 




replicates were lysed independently, and RNA was isolated and converted 
into cDNA in an independent manner for each biological replicate. Levels of 



























































4.1 SILENCING THE EXPRESSION OF PMCA4 IN HUMAN ENDOTHELIAL 
CELLS BY TRANSFECTING siRNAs TARGETING PMCA4. 
4.1.1 KNOCK-DOWN OF PMCA4 AT RNA LEVEL 
As we have mentioned in section 2, we have previously reported that 
endothelial PMCA4 inhibits VEGF-induced angiogenesis by downregulating 
the activity of the calcineurin/NFAT pathway (Baggot et al., 2014; Kurusamy 
et al., 2017). However, whether PMCA4 also regulates other signalling 
pathways activated by VEGF in endothelial cells is unknown at present.  
As a first step to investigate this question, this work has evaluated whether 
PMCA4 silencing in endothelial cells affects to the expression of VEGF-
induced critical angiogenic molecules such as components of the notch 
signalling pathway, extracellular matrix proteins (ECM) or cell adhesion 
molecules (CAM). Knock-down experiments were conducted in Human 
umbilical vein endothelial cells (HUVECs) by transfection of a siRNA targeting 
specifically human PMCA4 (si-PMCA4). HUVECs transfected with a non-
targeting siRNA (si-NT) were used as control. Four independent experiments 
with three replicates each were done (n=12) in total. Figure 4.1.1.i depicts a 
significant, strong reduction (around 90% reduction) in PMCA4 RNA 
expression in HUVECs transfected with si-PMCA4 compared to those 









Figure 4.1.1.i. siRNA-mediated PMCA4 silencing in endothelial cells 
leads to a strong reduction in PMCA4 expression at the RNA level. 
Histograms show data as mean ± SE, n=12.  **** indicates p<0.0001. Statistical 
analysis was done using unpaired, two-tailed, Student t test to verify deviation 
between the independent experiments when comparing siRNA-NT and 
siRNA-PMCA4 transfected cells.  
 
4.1.2 PROTEIN LEVEL DETECTION BY WESTERN BLOT 
Consistent with the RNA data, western blot analysis of protein lysates isolated 
from HUVEC transfected with siRNA-NT (control) or siRNA-PMCA4 verified 
the knockdown of PMCA4 expression at protein level. As it can be seen in 
Figure 4.1.2.i, a band corresponding to a protein of the molecular weight 
expected for PMCA4 (135 KDa) was detected by western blot analysis in 
protein lysates isolated from siNT-transfected HUVECs using an anti-PMCA4 
specific antibody. PMCA4 expression was, however, undetected in proteins 
from siPMCA4-transfected cells, confirming successful knockdown of PMCA4 
expression at protein level. Triplicates of two independent experiments are 
shown. Protein expression of α-tubulin (50 KDa) is shown as loading control, 
ruling out that lack of PMCA4 detection could be the consequence of 







Figure 4.1.2.i. Western blot analysis of PMCA4 after siRNA-mediated 
silencing of PMCA4 expression in human endothelial cells. PMCA4 
protein expression in whole lysates of HUVEC transfected with siRNA-NT or 
siRNA-PMCA4 was determined using an anti-PMCA4 mouse monoclonal 
antibody JA3 (α-PMCA4). Levels of tubulin were analysed in parallel as 
loading control. Images show results generated from 2 independent 





                        
 
 




4.2 ANALYSES OF CHANGES IN GENE EXPRESSION CAUSED BY 
PMCA4 SILENCING IN ENDOTHELIAL CELLS 
Notch signalling activation, and degradation of the extracellular matrix are two 
critical events required during the onset of angiogenesis (described in section 
1.3 of introduction). Therefore, potential changes in the expression of genes 
related to these cellular processes have been investigated in this study using 
endothelial cells where the expression of PMCA4 was significantly reduced by 
siRNA-mediated silencing.  
4.2.1 SCREENING OF A GENE ARRAY RELATED TO NOTCH 
SIGNALLING PATHWAY 
In order to verify if PMCA4 silencing regulates the Notch signalling pathway 
and the genes that code for proteins involved in Notch signalling during 
angiogenesis, a PCR-based gene array consisting of oligonucleotides to 
detect the expression of 84 genes important in notch signalling was screened 
with RNA isolated from HUVECs transfected with si-NT (control) or siPMCA4. 
Transfected cells were stimulated with VEGF (25 ng/mL) for 1 hour prior to 
RNA isolation. Expression of DLL1 (Delta like ligand-1), FOS, ID1 (Inhibitor of 
DNA binding 1), NOTCH3 and LFNG (O-Fucosylpeptide 3-Beta-N-
Acetylglucosaminyltransferase) was significantly enhanced by PMCA4 
silencing (figure 4.2.1.i). The higher increment was observed in the expression 
of FOS that was upregulated 7.68-fold. DLL1 was upregulated 2.77-fold. 
Interestingly, the expression of DLL4, another key Notch ligand expressed in 
endothelial cells, remained unchanged. ID1, NOTCH3 and LFNG were also 
upregulated just above the cut-off of 2-fold compared to control siNT 
transfected cells. Hey1 (Hes Related Family BHLH Transcription Factor With 




although differences with respect to control did not reach statistical 
significance. Knockdown of PMCA4 did not result in any significant 
downregulation in the expression of the genes studied in the array (figure 













Figure 4.2.1.i. Volcano plot depicting changes in the expression of genes 
related to the Notch signalling pathway after PMCA4 silencing in 
endothelial cells. PMCA4 was knocked down in HUVECs, and cells 
subsequently stimulated with VEGF (25 ng/mL) for 1 hour. Unchanged gene 
expression is denoted by a solid vertical line. Changes in gene expression lies 
on either side of this line, with dotted vertical lines indicating a cut-off in fold 
change expression of +2 (right dotted line) or 0.5 (left dotted line). Results are 
represented as mean of three independent gene array screening assays. The 
horizontal line marks statistical significance level p<0.05. Red dots represent 
upregulation of gene expression above the cut-off. Changes in gene 












Table 4.2.1.a. List of 84 genes screened in RT2 profiler PCR array 
depicting changes in genes related to the Notch signalling pathway after 
PMCA4 silencing in endothelial cells.  
Analysis was performed using the GeneGlobe Data Analysis Center resource 
https://geneglobe.qiagen.com/us/analyze/. Genes upregulated more than 2-
fold (cut-off) with P values <0.05 are highlighted in red boxes. Blue boxes 
indicate gene where expression was increased more than 2-fold but not 
significantly (p>0.05). The table shows comments; A, B, denoting that 
amplification of that gene required a high number of PCR cycles and the result 
is not reliable. Results with AVGDCt around 10 were not considered. Group 1 
denotes results from si-PMCA4 transfected cells stimulated with VEGF for 1 
hour. Control group denotes results from si-NT transfected cells stimulated 




4.2.2 SCREENING OF GENE ARRAY RELATED TO EXTRA CELLULAR 
MATRIX AND CELL ADHESION MOLECULES 
An RT2 profiler PCR array consisting of 84 genes related to extracellular matrix 
and cell adhesion molecules, was analysed by qPCR. Results shown in Figure 
4.2.2.i and table 4.2.2.a demonstrate that the expression of 8 genes; SELL 
(Selectin L), SELP (Selectin P), SELE (Selectin E), ADAMTS-1 (ADAM 
Metallopeptidase With Thrombospondin Type 1 Motif 1), SPP1 (Secreted 
Phosphoprotein 1), COL14A1 (Collagen 14A1), VTN (Vitronectin), ITGB4 
(Integrin Subunit Beta 4) increased significantly in PMCA4-silenced HUVEC 
stimulated with VEGF (25 ng/mL) for 3 hours. MMP10 (Matrix metalloprotease 
10) was downregulated by 2-fold. PMCA4 knockdown did not change the 
expression of other genes included in the array (Figure 4.2.2.i and Table 
4.2.2.a). Highest changes were observed in the expression of SPP1, with an 
increment of 9.31-fold, and ADAMTS-1, with 4.68-fold increment. ITGB4 with 
fold change 2.35, VTN with fold change 2.4, VCAM-1 with fold change 2.07, 
COL14A1 with fold change 2.73, SELL with fold change 2.71, SELE with fold 
change 2.26, and SELP with fold change 3.15, show lower but significant 
increments in expression in si-PMCA4 transfected cells (Figure 4.2.2.i and 
Table 4.2.2.a). These results suggest that PMCA4 is implicated in the 
regulation of these genes and the cellular processes involving these genes. 
Analysis of gene array using the “Qiagen GeneGlobe Data Analysis” resource 
https://geneglobe.qiagen.com/us/analyze indicated that the number of cycles 
required for PCR amplification of some genes was very high and the results 
are unreliable (genes with comment A or B in Table 4.2.2.a). Results from 






Figure 4.2.2.i. PMCA4 gene knockdown in HUVEC shows changes in the 
expression of genes related to ECM-CAM. PMCA4 was knocked down in 
HUVEC, and cells subsequently stimulated with VEGF (25 ng/mL) for 3 hours. 
Unchanged gene expression is denoted by a solid vertical line. Changes in 
gene expression lay on either side of this line, with dotted vertical lines 
indicating a cut-off in fold change expression of +2 (right dotted line) or 0.5 
(left dotted line). Results are represented as mean of three independent gene 
array screening assays. The horizontal line marks statistical significance level 
p<0.05. Red dots represent upregulation of gene expression above the cut-
off. Changes in gene expression below cut-off are presenting by black dots.  






Table 4.2.2.a. List of 84 genes screened in RT2 profiler PCR array 
depicting changes in genes related to ECM-CAM after PMCA4 silencing 
in endothelial cells. Analysis was performed using the GeneGlobe Data 
Analysis Center resource https://geneglobe.qiagen.com/us/analyze/. Genes 
upregulated more than 2-fold (cut-off) with P values <0.05 are highlighted in 
red boxes. Green box indicates a gene where expression was reduced 50%. 
Comments “A” or “B” denote that amplification of that gene required a high 
number of PCR cycles and the result is not reliable. Results with AVGDC t 
around 10 were not considered. Group 1 denotes results from si-PMCA4 
transfected cells stimulated with VEGF for 3 hours. Control group denotes 





4.3 VALIDATION OF DIFFERENTIAL GENE EXPRESSION OF PMCA4-
TARGET GENES AFTER PMCA4 SILENCING IN ENDOTHELIAL CELLS 
ISOLATED FROM LARGE VESSELS (HUMAN UMBILICAL VEIN 
ENDOTHELIAL CELLS, HUVEC) OR THE MICROVASCULATURE 
(HUMAN DERMAL MICROVASCULAR ENDOTHELIAL CELLS, HDMEC) 
 
4.3.1 VALIDATION OF GENES IMPLICATED IN NOTCH SIGNALLING 
PATHWAY USING TAQMAN qPCR TECHNIQUE. 
To verify the results obtained from the screening of the array of genes 
implicated in notch signalling we performed TaqMan-based qPCR using RNA 
isolated from control or PMCA4-silenced HUVECs. The figures 4.3.1.i - 
4.3.1.iii show the RNA expression of DLL1, Hey1, DLL4 in transfected cells at 
resting conditions and after stimulation with VEGF (25 ng/mL) at various time 
intervals. Data were analysed for statistical significance using 2-way ANOVA, 
with post-hoc multiple comparison Bonferroni’s test. Expression of RNA levels 
for DLL1 and Hey1 was not affected by PMCA4 silencing in resting cells, 
However, expression of these genes was strongly enhanced in PMCA4-
lacking cells after stimulation with VEGF for 30 and 60 minutes. Consistent 
with the data obtained from gene array experiments, expression of DLL4 was 
unaffected by PMCA4 silencing in HUVEC cells.  Figure 4.3.1.iv. show that 
RNA levels of cFOS were highly upregulated in HUVECs that were silenced 
for PMCA4 and stimulated with VEGF for 1h. Altogether, these results further 
reinforce the involvement of PMCA4 as a regulator of the expression of genes 














        
 
 
Figure 4.3.1.i. Validation of DLL1 RNA expression during PMCA4 gene 
silencing in VEGF-stimulated HUVEC. PMCA4 gene knockdown strongly enhances 
VEGF-induced upregulation of DLL1 gene expression in HUVEC. HUVEC transfected with si-
NT (blue line) or si-PMCA4 (red line) were stimulated with VEGF (25ng/mL) at the times 
indicated on the x-axis. Expression of DLL1 was normalised to expression of the Hprt-1 
housekeeping gene in the same samples. Data are presented as mean ± SE, n=9. Data were 
analysed for statistical significance differences by two-way ANOVA with post-hoc multiple 
comparison Bonferroni’s test. &, indicates p<0.05 at 3 hours, **** indicates p<0.0001 at 0.5 
hours, # # # # indicates p<0.0001 at 1 hour, and ns, indicates non-significant differences, when 
the values of DLL1 expression in si-PMCA4 transfected cells were compared to those in si-






































Figure 4.3.1. ii. Validation of Hey1 RNA expression during PMCA4 gene 
silencing in VEGF-stimulated HUVEC. PMCA4 gene knockdown strongly enhances 
VEGF-induced upregulation of Hey1 gene expression in HUVEC. HUVEC transfected with si-
NT (blue line) or si-PMCA4 (red line) were stimulated with VEGF (25ng/mL) at the times 
indicated on the x-axis. Expression of Hey1 was normalised to expression of the Hprt-1 
housekeeping gene in the same samples. Data are presented as mean ± SE, n=9. Data were 
analysed for statistical significance differences by two-way ANOVA with post-hoc multiple 
comparison Bonferroni’s test. &, indicates p<0.05 at 3 hours, **** indicates p<0.0001 at 0.5 
hours, # # # # indicates p<0.0001 at 1 hour, and ns, indicates non-significant differences, when 
the values of Hey1 expression in si-PMCA4 transfected cells were compared to those in si-







































Figure 4.3.1.iii. Validation of DLL4 RNA expression during PMCA4 gene 
silencing in VEGF-stimulated HUVEC. PMCA4 gene knockdown does not alter the 
expression of DLL4 in HUVEC. HUVEC transfected with si-NT (blue line) or si-PMCA4 (red 
line) were stimulated with VEGF (25ng/mL) at the times indicated on the x-axis. Expression 
of DLL4 was normalised to the expression of the Hprt-1 housekeeping gene in the same 
samples. Data are presented as mean ± SE, n=9. Data were analysed for statistical 
significance differences by two-way ANOVA with post-hoc multiple comparison Bonferroni’s 
test. ns, indicates non-significant differences, when the values of Hey1 expression in si-




Figure 4.3.1.iv. Validation of c-Fos RNA expression during PMCA4 gene 
silencing in VEGF-stimulated HUVEC. PMCA4 gene knockdown strongly enhances 
VEGF-induced upregulation of c-Fos gene expression in HUVEC. HUVEC transfected with si-
NT or si-PMCA4 were left unstimulated (control) or stimulated with VEGF (25 ng/mL) for 1 
hour. Expression of c-Fos was normalised to the expression of the Hprt-1 housekeeping gene 
in the same samples. Data are presented as mean ± SE, n=9. Data were analysed for 
statistical significance differences by One-way ANOVA with post-hoc Tukey’s multiple 




































4.3.2 RNA EXPRESION OF GENES RELATED TO ECM-CAM 
SIGNALLING PATHWAY IN HUVEC 
To verify the results obtained from the screening of the array of genes 
encoding components of the extracellular matrix and cell adhesion proteins, 
we performed TaqMan-based qPCR using RNA isolated from control or 
PMCA4-silenced HUVEC. Figures 4.3.2.i - 4.3.2.v shows RNA expression of 
ADAMTS-1, VCAM-1, SELE, SELL, and SELP in resting cells and after 
stimulation with VEGF (25 ng/mL) for 3 hours. PMCA4 gene knockdown 
enhanced the VEGF-dependent upregulation of ADAMTS1, SELE and 
VCAM1 in HUVEC. In the case, of SELL and SELP, PMCA4-knockdown 
increased the expression of these genes under basal conditions 
independently of any further stimulation. 
                       
Figure 4.3.2.i. Validation of ADAMTS-1 RNA expression during PMCA4 
gene silencing in VEGF-stimulated HUVEC. PMCA4 gene knockdown strongly 
enhances VEGF-induced upregulation of ADAMTS-1 gene expression in HUVEC. HUVEC 
transfected with si-NT or si-PMCA4 were left unstimulated (control) or stimulated with VEGF 
(25 ng/mL) for 3 hours. Expression of ADAMTS-1 was normalised to the expression of the 
Hprt-1 housekeeping gene in the same samples. Data are presented as mean ± SE, n=9. 
Data were analysed for statistical significance differences by One-way ANOVA with post-hoc 





                            
Figure 4.3.2.ii. Validation of SELE RNA expression during PMCA4 gene 
silencing in VEGF-stimulated HUVEC. PMCA4 gene knockdown strongly enhances 
VEGF-induced upregulation of SELE gene expression in HUVEC. HUVEC transfected with 
si-NT or si-PMCA4 were left unstimulated (control) or stimulated with VEGF (25ng/mL) for 3 
hours. Expression of SELE was normalised to the expression of the Hprt-1 housekeeping 
gene in the same samples. Data are presented as mean ± SE, n=9. Data were analysed for 
statistical significance differences by One-way ANOVA with post-hoc Tukey’s multiple 
comparison test. * indicates (p<0.05). ns= non-significant. 
 
 
Figure 4.3.2.iii. Validation of SELP RNA expression during PMCA4 gene 
silencing in VEGF-stimulated HUVEC. PMCA4 gene knockdown strongly enhances 
upregulation of SELP gene expression under basal condition in HUVEC. HUVEC transfected 
with si-NT or si-PMCA4 were left unstimulated (control) or stimulated with VEGF (25ng/mL) 
for 3 hours. Expression of SELP was normalised to the expression of the Hprt-1 housekeeping 
gene in the same samples. Data are presented as mean ± SE, n=9. Data were analysed for 
statistical significance differences by One-way ANOVA with post-hoc Tukey’s multiple 






Figure 4.3.2.iv. Validation of VCAM1 RNA expression during PMCA4 
gene silencing in VEGF-stimulated HUVEC. PMCA4 gene knockdown strongly 
enhances VEGF-induced upregulation of VCAM1 gene expression in HUVEC. HUVEC 
transfected with si-NT or si-PMCA4 were left unstimulated (control) or stimulated with VEGF 
(25ng/mL) for 3 hours. Expression of VCAM1 was normalised to the expression of the Hprt-1 
housekeeping gene in the same samples. Data are presented as mean ± SE, n=9. Data were 
analysed for statistical significance differences by One-way ANOVA with post-hoc Tukey’s 
multiple comparison test. * indicates (p<0.05). ns = non-significant. 
 
Figure 4.3.2.v. Validation of SELL RNA expression during PMCA4 gene 
silencing in VEGF-stimulated HUVEC. PMCA4 gene knockdown strongly enhances 
upregulation of SELL gene expression under basal conditions in HUVEC. HUVEC transfected 
with si-NT or si-PMCA4 were left unstimulated (control) or stimulated with VEGF (25ng/mL) 
for 3 hours. Expression of SELL was normalised to the expression of the Hprt-1 housekeeping 
gene in the same samples. Data are presented as mean ± SE, n=9. Data were analysed for 
statistically significant differences by One-way ANOVA with post-hoc Tukey’s multiple 





4.3.3 RNA EXPRESSION OF GENES RELATED TO ECM-CAM IN 
HDMECs 
To elucidate whether the results observed in HUVEC were reproducible in 
other cell types of endothelial cells, we silenced PMCA4 gene expression in 
Human Dermal Microvascular Endothelial cells (HDMECs) (figure 4.3.3.i). The 
figures 4.3.3.ii – 4.3.3.vi shows RNA expression of ADAMTS-1, SELE, SELL, 
SELP, and VCAM-1 in HDMEC after PMCA4 gene silencing, and treatment 
with or without the pro-angiogenic stimulus VEGF (25ng/mL) for 3 hours. 
Comparison of the results in the two cell types showed that the expression of 
genes related to ECM-CAM is varying between different cell types. We found 
that the gene ADAMTS-1 is upregulated in both HUVEC and HDMEC after 
PMCA4 silencing (figure 4.3.2.i and figure 4.3.3.i). We have also seen that 
expression of SELE in figure 4.3.2.ii is upregulated in HUVEC when stimulated 
with VEGF as expected, whereas in HDMECs the expression of SELE did not 
change after VEGF stimulation of the cells (figure 4.3.3.ii). Figure 4.3.2.v 
shows that SELL levels are up-regulated by PMCA4 silencing even under 
unstimulated conditions in HUVEC, which is the same case as we observe in 
HDMECs (figure 4.3.3.iv). HUVEC PMCA4-silenced cells showed upregulated 
expression of SELP under basal conditions (Figure 4.3.2.iii) whereas in 
HDMEC (figure 4.3.3.v). PMCA4 silencing did not alter SELP level in basal 
conditions or after stimulation VEGF. Finally, PMCA4 silencing leads to 
upregulated levels of VCAM1 gene expression in VEGF-stimulated HUVEC 
(figure 4.3.2.iv) whereas PMCA4 knockdown does not affect expression of this 




                                        
Figure 4.3.3.i. siRNA-mediated PMCA4 silencing leads to a strong 
reduction in PMCA4 expression at the RNA level in HDMECs. Histograms 
show data as mean ± SE, n=9.  **** indicates p<0.0001. Statistical analysis was done using 
unpaired, two-tailed, Student t test to verify deviation between the independent experiments 
when comparing siRNA-NT and siRNA-PMCA4 transfected cells.  
 
Figure 4.3.3.ii. Validation of ADAMTS-1 RNA expression during PMCA4 
gene silencing in VEGF-stimulated HDMEC. PMCA4 gene knockdown strongly 
enhances VEGF-induced upregulation of ADAMTS-1 gene expression in HDMECs. HDMEC 
transfected with si-NT or si-PMCA4 were left unstimulated (control) or stimulated with VEGF 
(25ng/mL) for 3 hours. Expression of ADAMTS-1 was normalised to the expression of the 
Hprt-1 housekeeping gene in the same samples. Data are presented as mean ± SE, n=9.. 
Data were analysed for statistical significance differences by One-way ANOVA with post-hoc 





Figure 4.3.3.iii. Validation of SELE RNA expression during PMCA4 gene 
silencing in VEGF-stimulated HDMEC. PMCA4 gene knockdown remains 
unchanged under basal conditions in VEGF-induced SELE gene expression in HDMECs. 
HDMEC transfected with si-NT or si-PMCA4 were left unstimulated (control) or stimulated with 
VEGF (25 ng/mL) for 3 hours. Expression of SELE was normalised to the expression of the 
Hprt-1 housekeeping gene in the same samples. Data are presented as mean ± SE, n=9. 
Data were analysed for statistical significance differences by One-way ANOVA with post-hoc 
Tukey’s multiple comparison test. ** indicates p<0.01; ns= non-significant. 
 
 
Figure 4.3.3.iv. Validation of SELL RNA expression during PMCA4 gene 
silencing in VEGF-stimulated HDMEC. PMCA4 gene knockdown remains 
upregulated in basal conditions in VEGF-induced SELL gene expression in HDMECs. 
HDMEC transfected with si-NT or si-PMCA4 were left unstimulated (control) or stimulated with 
VEGF (25 ng/mL) for 3 hours. Expression of SELL was normalised to the expression of the 
Hprt-1 housekeeping gene in the same samples. Data are presented as mean ± SE, n=9. 
Data were analysed for statistical significance differences by One-way ANOVA with post-hoc 





Figure 4.3.3.v. Validation of SELP RNA expression during PMCA4 gene 
silencing in VEGF-stimulated HDMEC. PMCA4 gene knockdown remains 
unchanged in VEGF-induced SELP gene expression in HDMECs. HDMEC transfected with 
si-NT or si-PMCA4 were left unstimulated (control) or stimulated with VEGF (25 ng/mL) for 3 
hours. Expression of SELP was normalised to the expression of the Hprt-1 housekeeping 
gene in the same samples. Data are presented as mean ± SE, n=9. Data were analysed for 
statistical significance differences by One-way ANOVA with post-hoc Tukey’s multiple 
comparison test. ns= non-significant. 
 
 
Figure 4.3.3.vi. Validation of VCAM1 RNA expression during PMCA4 
gene silencing in VEGF-stimulated HDMEC. PMCA4 gene knockdown remains 
unchanged in VEGF-induced VCAM1 gene expression in HDMECs. HDMEC transfected with 
si-NT or si-PMCA4 were left unstimulated (control) or stimulated with VEGF (25 ng/mL) for 3 
hours. Expression of VCAM1 was normalised to the expression of the Hprt-1 housekeeping 
gene in the same samples. Data are presented as mean ± SE, n=9. Data were analysed for 
statistical significance differences by One-way ANOVA with post-hoc Tukey’s multiple 




4.4. QUANTIFICATION OF PMCA4 RNA EXPRESSION IN AGING 
HUVEC 
Advanced aging of cells leads to sensitisation of endothelial cells to apoptosis 
and therefore cell death causing atherosclerosis due to the impairment within 
the vessel walls (Hoffmann et al., 2001). PMCA4 has been implicated as a 
regulator of apoptosis and thus we decided to analyse the RNA expression of 
PMCA4 in primary cells along different passages of in vitro culture. RNA 
isolated from HUVEC cultured in vitro at various passages showed a 
progressive increase in the levels of PMCA4, reaching maximal levels after 11 
passages where the expression of PMCA4 increased more than 2.5-fold 
compared to that in young cells cultured for low passage numbers (Figure 
4.4.1.i). These results indicate that PMCA4 RNA levels increase in cell culture 
along with passage number, suggesting that there might be a link between 
expression of PMCA4 and endothelial cell senescence. 
         































Figure 4.4.1.i. Bar chart representing increase in levels of PMCA4 in 
aging HUVECs. RNA levels of PMCA4 were obtained from aging HUVECs cultured from 
passage 3-15. Statistical analysis was done using one-way ANOVA, Tukey’s Multiple 
comparison test, comparing the RNA levels of day 3 with that of others. *** denotes the 
statistical significance p < 0.001, ** denotes statistical significance of p<0.01, * denotes p<0.05 



































Our previous findings have demonstrated that the protein PMCA4 plays a 
crucial role as a negative regulator of angiogenesis by downregulating the 
activity of intracellular signalling pathways (such as the calcineurin-NFAT 
pathway) involved in angiogenesis progression (Baggot et al., 2014; 
Kurusamy et al., 2017). However, we hypothesised in this study that PMCA4 
might as well regulate angiogenesis by controlling the activity of other 
signalling pathways in endothelial cells stimulated with VEGF. A prominent 
regulator of VEGF-induced signalling in endothelial cells is the Notch signaling 
pathway, that plays a central coordinator role in endothelial cell proliferation, 
migration, and tubular morphogenesis during blood vessels formation in 
response to VEGF stimulation. The Notch pathway is involved in selection of 
endothelial tip cell versus stalk cells establishing its importance in the 
response to VEGF activation and in the fate of the nascent blood vessel. A 
study by Adam et al., 2013, demonstrated that when HUVECs were 
subjected to a time dependent exposure to VEGF, there was a steady 
increase in the mRNA levels of DLL4 and Hey1 at 30 minutes and 1-hour of 
stimulation, decreasing after 3 hours of adding the stimulus. Here, we show 
that time-point analysis of DLL1, Hey1, and DLL4 gene expression in HUVEC 
stimulated with VEGF showed transient increased expression of these genes 
peaking at 0.5h and 1h, and decay after 3h post-stimulation (Figure 4.3.1.i-
4.3.1.iv). These results are consistent with the results observed in the study 
by Adam et al., 2013. Our study has also revealed that knockdown of PMCA4 
results in a significant enhancement on the VEGF-induced upregulation of 
DLL1 (2.77-fold enhancement, Figure 4.3.1.ii), whereas DLL4 expression 




showed that heterozygous loss of DLL1 resulted in impaired arteriogenesis 
but, not microvascular angiogenesis in the ischemic limbs of mice subjected 
to experimentally induced hindlimb ischemia. The study by Limbourg et al 
suggests that DLL1 is an important notch ligand which regulates 
arteriogenesis and is shown to be predominantly expressed in arterial 
endothelium. They successfully demonstrated in in vivo models that Dll1 
regulates arteriogenesis via Ephrin B2 receptor expressed on the EC and 
increased the expression of arterial markers Hes1 and Hey1. This is also 
consistent with our results which shows enhancement VEGF-dependent 
upregulation of Hey1 in cells where PMCA4 expression was knocked-down. 
Interestingly, work by our laboratory has shown that blood reperfusion in the 
ischaemic limbs of Pmca4-/- mice is higher than in those of littermate wild-
types (Baggott et al., 2014). Further research is necessary to ascertain 
whether increased blood reperfusion in the ischaemic limbs of Pmca4 KO 
mice is the result of enhanced arteriogenesis and/or angiogenesis. Moreover, 
it would be very interesting to determine the expression of DLL1 in the arteries 
of PMCA4 KO animals and compare it to that in wild-type mice.  
DLL4 plays a vital role in sprouting angiogenesis by maintaining the tip cell 
characteristics in the vascular beds thereby driving proliferation and migration 
of blood vessels in a VEGF dependent manner and functions by repressing 
the expression of Nrp1/Vegfr2 and maintains notch signalling. DLL1+/- EC 
specific ablation models survived until birth in which, DLL4 was expressed but 
was unable to sustain notch activity or maintain arterial identity and its markers 
such as Hey1, Ephrin B2, Nrp1 thus permitting the expression of COUP-TF II 




morphological defects in mouse models (Fischer et al., 2004). Hey1 and Hey2 
genes together are required for embryonic vascular development and are 
essential in mediating arterial fate decision (Fischer et al., 2004). Therefore, 
DLL1-notch signalling, but not DLL4, is important in expression of arteries 
(Gessler et al., 2009).  Although DLL1 and DLL4 show structural similarities, 
they are having functional differences and their ectodomains play a vital role 
in receptor selectivity (Tveriakhina et al., 2018). It will be very interesting to 
analyse whether PMCA4 plays any role on post-natal development of blood 
vessel in mouse retina. Our results show that lack of PMCA4 in endothelial 
cells does not alter VEGF-induced expression of DLL4, which is a pivotal 
regulator of physiological post-natal retinal angiogenesis (Suchting et al., 
2007). However, we have seen that lack/inhibition of PMCA4 function 
interferes with pathological angiogenesis processes (Baggot et al., 2014; 
Kurusamy et al., 2017). Therefore, the exact role of PMCA4 in physiological 
versus pathological angiogenesis deserves further investigation.  
AP-1 is a heterodimeric transcription factor that combines cFOS and JUN 
proteins critical for regulating cellular growth and differentiation (Lee et al., 
1998). In a study by Armesilla et al., 1999, cFOS expression was upregulated 
by short exposure of HUVEC to VEGF stimulation. Similarly, in a study by 
Holmes and Zackary 2004, when HUVECs were stimulated with 25 ng/ml 
VEGF an increase in mRNA levels of cFOS for a short exposure up to 45 
minutes was observed which gradually decreased after 90 minutes of 
stimulus, which is also coincident with our data showing upregulation of cFOS 
at short VEGF stimulation of 1h. Also, in agreement with our results, Aung et 




in reduction of cFOS RNA expression. Our results show an increase in cFOS 
levels in HUVECs when we silence PMCA4 expression. cFOS is an immediate 
responsive transcription factor controlling the expression of many target 
genes. Further experiments in PMCA4-silenced cells are required to 
determine the effects of enhanced c-Fos expression on the transcriptional 
regulation of target genes and the endothelial cell response to VEGF 
stimulation. Increasing evidence from literature shows that the process of 
angiogenesis begins with degradation of extracellular matrix resulting in new capillary 
sprout formation which is guided by hypoxia induced growth factors (Houck et al., 
1992). For this reason, we decided to analyse the effect of PMCA4 silencing on the 
endothelial expression of metalloproteinases, on components of the extracellular 
matrix, and on cell adhesion molecules. Our results in HUVEC show upregulated 
ADAMTS1 expression in cells stimulated with VEGF for 3 hours (Figure 4.3.2.i). 
These results are consistent with data previously published by Oller et al., 2015. 
Further to VEGF-dependent upregulation, our results demonstrate that lack of 
PMCA4 enhances ADAMTS-1 expression in endothelial cells (HUVEC and HDMEC). 
Our previous work indicates that lack of PMCA4 promotes angiogenesis (Baggott et 
al., 2014; Kurusamy et al., 2017) and in this study we demonstrate that lack of PMCA4 
enhances the expression of ADAMTS1. Therefore, it would be logical to think that 
PMCA4-mediated enhanced expression of ADAMTS1, would participate in increased 
degradation of the ECM, and therefore promote angiogenesis. However, several 
reports have indicated a negative role for ADAMTS1 in the regulation of angiogenesis 
(Iruela-Arispe et al., 2003; Luque et al., 2003; Lambert et al., 2020). It is thought that 
several factors co-operate with ADAMTS1 to exert this inhibitory effect on 
angiogenesis (Lambert et al., 2020). Thus, although we have only studied in this work 
the effect of PMCA4 silencing on the expression of a small selection of endothelial 




transcriptome, for example by performing RNA-Seq experiments, to determine 
whether the expression of ADAMTS1 co-factors is also altered by lack of PMCA4.   
Our results also show that PMCA4 silencing enhances the VEGF-induced 
upregulation of the cell adhesion molecules E-Selectin and VCAM-1 in 
HUVEC cells. E-Selectin and VCAM-1 are well-known endothelial mediators 
of leukocyte adhesion to the endothelium during inflammation (Ley et al., 
2007). Additionally, several groups have reported that expression of these 
molecules in endothelial cells in response to VEGF play an important role in 
angiogenesis (Nguyen et al., 1993; Luo et al., 1999; Koch et al., 1995). Our 
results suggest that enhancement in the expression of these molecules in 
PMCA4-silenced cells, would support the increase in angiogenic processes 
previously reported in cells lacking PMCA4 (Baggott et al., 2014; Kurusamy et 
al, 2017). Consistent with a positive role as inducers of angiogenesis, we were 
expecting that our results using HDMEC would yield similar results to those 
observed in HUVEC. However, stimulation with VEGF did not upregulate E-
Sel or VCAM-1 expression in HDMEC (Figure 4.3.3.iii). Furthermore, PMCA4 
knockdown in HDMEC neither enhanced the expression of these genes 
(Figure 4.3.3.iii). It will be necessary to repeat these experiments using 
different batches of HDMEC, and also to use different microvascular cell types 





Figure 5.1. Graphical representation of CaN/NFAT and NFκB signalling 
pathway which leads to increase of ADAMTS-1, SELE and VCAM-1 
regulated by VEGF/VEGFR signalling. Pathway indicated in green denotes the 
CaN/NFAT signalling, and pathway in red denotes NFκB signalling. It is unknown 
whether PMCA4 regulates NFκB signalling, and this is highlighted by “?” in the figure. 
Various studies showed that VEGF increased the mRNA and protein level 
expression of metalloproteinase and cell adhesion molecules like ADAMTS-1, 
SELE and VCAM-1 in a CaN/NFAT or NFκB signalling pathway (Oller et al., 
2015, Stannard et al., 2007, Kim et al., 2001). In our experiments we 
successfully demonstrated that PMCA4 silencing and stimulation with VEGF 
upregulates the expression of ADAMTS-1, SELE, and VCAM-1 (Fig 5.1). 
Stannard et al. (2007) showed that preincubation of ECs with VEGF activates 
the endothelial cells to enhance SELE upregulation by TNF-α or IL-1β in a 
CaN/NFAT dependent pathway. However, Kim et al (2001) showed that VEGF 
induces SELE and VCAM-1 expression through the NFκB pathway.  It will be 
interesting to see if PMCA4 affects NFκB signalling leading to regulation of 
VCAM-1 and SELE expression (Fig 5.1), to determine if the enhancement in 
VEGF-induced expression of these genes observed in cells lacking PMCA4 




been previously demonstrated that VEGF stimulation is necessary for 
upregulation of ADAMTS-1 via CaN/NFAT pathway (Oller et al., 2015; Baggott 
et al., 2014). The authors also showed in their work that cyclosporin A (a well-
known inhibitor of calcineurin signalling) significantly reduced ADAMTS-1 
gene expression in response to VEGF. We have previously established that 
PMCA4 inhibits the CaN/NFAT pathway in endothelial cells (Kurusamy et al., 
2017). Therefore, in future experiments, it will be interesting to inhibit 
CaN/NFAT activity using CsA, and to check whether the enhancement in the 
VEGF-mediated expression of ADAMTS-1 due to PMCA4 knockdown is 
eliminated. In our results we see that P-Selectin levels are basally 
overexpressed in HUVEC silenced for PMCA4 expression. Auvinen et al., 
2014, showed that P-Selectin was present under physiological conditions in 
embryonic endothelial cells in mouse models starting from week 11, 
suggesting the involvement of P-Selectin in developmental angiogenic 
processes. Moreover, expression of P-selectin is elevated in the vitreous of 
patients with neovascular ocular diseases such as proliferative diabetic 
retinopathy (McLeod et al., 1995) suggesting a positive role in pathological 
angiogenesis. In this sense, lack of P-selectin impaired platelet deposition in 
tumors, and thus decreased secretion of VEGF by adherent platelets leading 
to a reduction in tumor angiogenesis (Qi et al., 2015). These works indicate 
that P-Selectin plays a positive role as a mediator of angiogenesis and 
therefore, elevated levels in PMCA4-silenced cells are concurrent with the 
increased angiogenesis previously reported by us in cells lacking PMCA4 
(Baggot et al., 2014; Kurusamy et al., 2017). L-Selectin, is a cell surface 




endothelium during inflammation (Tedder et al., 1995). Their levels tend to 
increase during post-ischemic conditions on the endothelial cells to induce 
adaptive migratory response to external stimulus (Ley., 2003). Simon et al., 
1999 in their paper described that in response to inflammatory stimulus, the 
endothelial cells express L-Selectin to capture the circulating leukocyte. Our 
study demonstrates that suppression of PMCA4 in both HUVEC and HDMEC 
results in an increase in the basal expression of L-Selectin. Yukami et al., 2007 
have reported that mice deficient in E-Selectin, P-Selectin, L-Selectin, and 
ICAM-1 show suppressed angiogenesis and significant delays in the process 
of wound healing, indicating that these molecules all co-operate as positive 
mediators of angiogenesis and would healing. It would be interesting to 
evaluate in further works whether suppression of PMCA4 can be used 
therapeutically to increase would healing.   
Cardiovascular diseases are common with increasing age. Thus, we were 
interested to quantify the expression of PMCA4 during aging. As an initial step 
we analysed the PMCA4 RNA expression in HUVECs along various 
passages. We demonstrated from two independent experiments that there 
was an increase in PMCA4 RNA levels which co-related with increasing cell 
passage. However, we have only seen the data of PMCA4 RNA levels in aging 
HUVECs and it would be interesting to quantify PMCA4 protein levels along 
increasing passages. In agreement with our results, Angenendt et al., 2020, 
have recently reported that expression of PMCA4 increases in the T-Cells of 
elderly mice. More experiments are needed to validate the expression of 
PMCA4 in other cell types and investigate the functional consequences of 


































 Knockdown of PMCA4 in HUVECs enhanced the VEGF-induced expression 
of genes related to the Notch signalling pathway, like DLL-1 and HEY1 
suggesting that PMCA4 regulates VEGF-induced Notch signalling by 
controlling the expression of gene encoding different molecules integrated in 
this pathway. 
 Lack of PMCA4 leads to upregulation of SELE, SELP, SELL, ADAMTS-1 and 
VCAM1 in HUVEC which are important genes related to ECM and cell 
adhesion biology. Upregulation of SELP and SELL in response to PMCA4 
silencing occurred in HUVEC cultured in basal conditions, whereas 
upregulation of ADAMTS-1, SELE, or VCAM-1 required stimulation with VEGF 
indicating that PMCA4 regulates the different pathways controlling the 
expression of these genes in basal or VEGF-stimulated conditions.    
 Analysis of gene expression changes in HDMEC lacking PMCA4 showed 
different results to those observed in HUVEC, indicating that PMCA4 might 
control different signalling pathways in different cellular types. 
 PMCA4 RNA levels significantly increased along passage number in cultured 
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